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ABSTRACT 
 
A MECHANISTIC STUDY IN THE NEPHROTOXICITY 
 OF P-AMINOPHENOL 
 
by R. Christopher Harmon 
The acetaminophen metabolite, p-aminophenol (PAP), is a known 
nephrotoxicant. The current study is directed at understanding the 
mechanism of this nephrotoxicity.  Renal cortical slices isolated from 
F344 rats were incubated with 0 – 0.5 mM PAP with or without 
pretreatments.  Renal slices exposed to PAP showed toxicity as 
measured by increased lactate dehydrogenase leakage (LDH), 
decreased pyruvate-stimulated gluconeogenesis, and decreased total 
adenine nucleotides.  There was, however, an increase in ATP as 
percent of total, implying maintained mitochondrial function.  These 
data show that PAP is directly toxic to renal cortical slices.    
Pretreatment with EDTA or EGTA provided protection from PAP-
induced LDH leakage, while EGTA-AM did not.  These data show 
that PAP toxicity is dependent on extracellular calcium and 
independent of small increases in intracellular calcium.  PAP 
exposure decreased total glutathione within 30 min, and marked 
depletion was evident at 120 min.  At 60 min, PAP increased 
glutathione disulfide (GSSG) as percent of total glutathione 
(%GSSG).  PAP exposure also increased 4-hydroxynonenal-
adducted proteins.  Pretreatment with ascorbate prevented PAP 
mediated increases in LDH, while reduced glutathione (GSH) or N-
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acetylcysteine did not prevent PAP toxicity.  These data support the 
hypothesis that PAP induces oxidative stress, which cannot be 
prevented by exogenous sulfhydryl containing compounds.  
Administration of pyruvate protected against PAP-induced time- and 
concentration-dependent effects on LDH and adenine nucleotides.  
Finally, pyruvate caused an increase in cellular total glutathione and 
reduced PAP effects on total glutathione and %GSSG.  These data 
imply that pyruvate protects from PAP toxicity through increasing the 
concentrations of total glutathione and recycling GSSG back to GSH.  
Pretreatment with glucose provided slight protection from LDH and 
increases in %GSSG.  Finally, pyruvate but not glucose induced a 
significant increase in NADPH, confirming the hypothesis that 
pyruvate protects through NADPH-dependent recycling of 
glutathione.  The greater degree of protection provided by pyruvate 
implies that pyruvate may provide a more readily available source for 
the prevention of oxidative stress.  Pyruvate protection from oxidative 
stress of PAP may be expanded to other toxins with oxidant 
mechanisms of toxicity.  These results could also be extrapolated to 
acetaminophen nephrotoxicity, and may provide the basis for future 
treatments.   
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 CHAPTER I 
 
Introduction 
Para-aminophenol (PAP) is a known renal toxicant.  People are exposed 
to PAP both directly and indirectly.  PAP is used in a wide variety of commercial 
and industrial applications, thus allowing for direct exposure.  Individuals can also 
be exposed to PAP through metabolism of precursor agents.  Acetaminophen 
(APAP) is known to be metabolized to PAP and may account for the majority of 
indirect PAP exposures, as it is one of the most commonly used analgesics in the 
USA and worldwide.  Individuals often misuse APAP both acutely (suicide 
attempts) and chronically (long-term exposure in chronic pain patients).  It is 
therefore of major scientific and medical interest to investigate the hazards 
associated with PAP.    
PAP, as a renal toxicant, has been studied in depth.  Much of this 
research has focused on the effects of PAP in the whole animal, specifically 
showing toxicity to the terminal segment of the proximal tubule.  Some research 
has looked at the metabolism of PAP in both in vivo and in vitro model systems.   
A vast majority of research has implicated glutathione and cysteine conjugates 
as probable metabolites for PAP intoxication in the in vivo model.  Little work, 
however, has been done to investigate the mechanistic toxicity of PAP.  This 
project sought to determine the mechanism of toxicity of PAP.  Investigations into 
the specific mechanistic toxicity induced by PAP were made possible using the 
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 renal cortical slice model.  Results from this work fill the gap in research between 
exposure to PAP and toxicity.  
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 CHAPTER II 
 
Review of Literature 
p-Aminophenol (PAP) is a known renal toxicant to which people are 
exposed both directly and indirectly.  Direct exposure to PAP may occur through 
occupational exposure as PAP is used in a wide variety of industrial applications 
(Kirk-Othmer, 1991).  PAP is a component in dyes used for textiles, hair, fur, and 
feathers as well as wood stains (Kirk-Othmer, 1991).  In addition, it is used as a 
reducing agent in photographic developing (Kirk-Othmer, 1991).  Indirect 
exposure to PAP occurs through metabolism of other compounds resulting in the 
formation of PAP.  One compound, aniline, is metabolized to PAP through 
oxidation at the para position.  Acetaminophen (APAP) is another compound 
metabolized to PAP (Carpenter and Mudge, 1981; Newton et al., 1982) (FIGURE 
1).  APAP may account for the majority of PAP exposures, as it is one of the 
most commonly used analgesics in the USA and worldwide.  Individuals often 
misuse APAP both acutely (suicide attempts) and chronically (long-term 
exposure in chronic pain patients) (Ellenhorn, 1997).  It is therefore of major 
scientific and medical interest to investigate the toxicity associated with PAP.  
NH
OH
C
O
CH3 NH2
OH
Deacylation
APAP PAP
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FIGURE 1.  Deacylation of APAP 
 The hepatotoxicity of APAP has been extensively characterized, as the 
liver is the major target organ for toxicity.  The effects on the kidney, however, 
are less well characterized.  It is known that APAP is in part metabolized to PAP 
through deacylation (Carpenter and Mudge, 1981; Newton et al., 1982).  It has 
been demonstrated that PAP is 5-10 times more potent than APAP as a 
nephrotoxicant in Fischer 344 (F344) rats (Newton et al., 1982).  Also, the 
histopathologic renal lesions produced in F344 rats by PAP are indistinguishable 
from those following APAP administration (Newton et al., 1985).  Newton has 
also shown that inhibition of deacylation reactions can attenuate APAP 
nephrotoxicity in F344 rats (Newton et al., 1985).  These data suggest that PAP 
is the probable toxic metabolite of APAP in the F344 rat model (FIGURE 1).  
In humans, a dose of 10 to 15 grams (140 to 250 mg/kg) of APAP has 
been shown to cause acute hepatotoxicity, while a dose of 20 to 25 g is 
potentially fatal (Ellenhorn et al., 1997).  Renal impairment has been reported in 
about 1% of patients who have ingested an overdose of APAP, while nearly all 
humans exposed to these doses experience hepatotoxicity without treatment 
(Campbell and Baylis, 1992).  Although peak disturbances in liver function are 
seen 2 to 4 days following an APAP overdose, renal impairment may only 
become evident after 1 week and return to normal 2 to 3 weeks after ingestion 
(Curry et al., 1982; Gabriel, 1982; Cobden et al., 1982).  Treatment with N-
acetylcysteine (NAC), a glutathione (nonspecific) precursor used for APAP 
overdose, can protect from APAP hepatotoxicity (Ellenhorn, 1997).  However, 
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 there is no improvement in renal function with NAC treatment, suggesting a 
different mechanism of toxicity (Jones and Vale, 1993).   
PAP is an acute nephrotoxin that produces severe necrosis of the 
proximal tubule in rats following a single injection (Davis et al., 1983; Shao and 
Tarloff, 1996).  Toxicity is localized to the pars recta (S3 segment) of proximal 
tubules of cortical nephrons in male F344 rats (Newton et al., 1982; Gartland et 
al., 1989) (FIGURE 2).   Doses above 100 mg/kg have caused an increase in 
blood urea nitrogen (BUN) at 24 hours (Newton et al., 1882).  Other studies have 
indicated decreased renal function as evidenced by a decreased uptake of 
organic ions after treatment (Newton et al., 1982; Rankin et al., 1996).   Work by 
Valentovic and Ball (1998) has shown that 0.25 mM PAP is directly toxic to renal 
cortical slices from F344 rats.     
Proximal Tubule 
 
S1 
glomerulus 
 
 Distal TubuleS2 
Cortex S3 
 
 
 Loop of
Henle 
Medulla 
 
 
FIGURE 2.  Diagrammatic Representation of the Nephron. 
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Because most of the above studies have been performed in F344 rat, this rat 
appears to be an excellent model for the investigation of PAP-induced 
nephrotoxicity. 
As stated above, APAP is known to be deacylated to PAP, which is 
thought to be an important metabolite in the development of nephrotoxicity in 
rats.  Species differences do, however, exist in APAP toxicity.  Work by Newton 
et al. (1985) has determined that for toxicity to occur in rats, APAP must be 
deacylated to PAP.  In contrast, evidence in mice suggests that deacylation does 
not occur and APAP is directly toxic to the kidney (Hart et al., 1991).  Regardless 
of species, covalent modification of cellular macromolecules appears to occur 
and may contribute to toxicity (Newton et al., 1985; Hart et al., 1991).  Strain 
differences in rats are also evident.  Specifically, F344 rats are more susceptible 
to both APAP and PAP toxicity than Sprague-Dawley rats (Newton et al., 1983b; 
Valentovic and Ball, 1996).  Furthermore, these differences may not be attributed 
to differences in cytochrome P450 (P450) activity or deacylation (Newton et al., 
1983b). 
Some researchers propose that mitochondria are a major target for PAP 
toxicity.  Lock et al. (1993) has demonstrated that PAP exposure to rabbit 
proximal tubules led to ATP depletion.  Crowe et al. (1977) has found that 
respiration, oxidative phosphorylation, and ATPase activity were inhibited in 
mitochondria isolated from the kidneys of PAP treated rats.  The investigators 
have further reported that mitochondria isolated from PAP treated rats 
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 demonstrated ultrastructural damage (Crowe et al., 1977). These findings 
suggest that mitochondria may be a target for the induction of PAP toxicity.   
Metabolism of APAP and PAP are of interest to the toxicity of PAP.  It is 
known that metabolism of APAP plays a direct role in the hepatic toxicity of 
APAP.  APAP is oxidized by P450 to N-acetyl-p-benzoquinone imine, which reacts 
with nucleophiles to alter cellular macromolecules (Patten et al., 1993).  The role 
of metabolism of APAP and PAP in renal toxicity is not as well characterized.   
Previous studies have shown that PAP may undergo oxidative 
metabolism.  PAP is oxidized enzymatically in vitro to benzoquinone imine by 
peroxidases, P450, and hemoglobin-dependent systems in erythrocytes (Josephy 
et al., 1983; Calder et al., 1979).    Work by Shao et al. (1997) in isolated 
proximal tubules from female Sprague-Dawley rats has shown that the hepatic 
S9 fraction increases PAP toxicity in the presence of reduced glutathione (GSH).  
This research has also reported that inactivation of microsomes with 1-
aminobenzotriazole, an inhibitor of P450, had no effect on PAP-induced toxicity 
relative to microsomes without 1-aminobenzotriazole (Shao et el., 1997).  
Pretreatment with P450 inhibitors, piperonyl butoxide (450 mg/kg) or cobalt 
chloride (60 mg/kg), has been shown to protect against 0.75 mmol/kg PAP-
induced renal necrosis in female Sprague-Dawley rats (Calder et al., 1979).   
Conversely, the administration of piperonyl butoxide has been shown to cause an 
increase in PAP nephrotoxicity in mice (Song et al., 1999). These studies 
indicate that PAP may be activated through metabolism and hepatic P450 may or 
 
 
7 
 may not be involved.  Clearly, further investigation is needed to clarify the role of 
oxidative metabolism in PAP toxicity.   
Some researchers support a glutathione conjugate of PAP as the toxic 
species for inducing nephrotoxicity.  It is proposed that such conjugates provide a 
means of concentration within the S3 segment of the proximal tubule.  Work by 
Klos et al. (1992) has identified glutathione conjugates as metabolites of PAP 
using hepatocytes isolated from Sprague-Dawley rats.  One of these conjugates, 
4-amino-3-S-glutathionylphenol, has been shown to be more toxic than PAP in 
F344 rats (Fowler et al., 1991).  Conversely, Lock et al. (1993) has found that a 
concentration of 1 mM 4-amino-3-S-glutathionylphenol did not decrease cell 
viability in isolated tubules from rabbit proximal tubules.  The isolated tubule 
model can, however, be scrutinized in that luminal access is not permitted, thus 
preventing processing and uptake.  Administration of buthionine S-sulfoximine, 
an inhibitor of glutathione synthesis, has been shown to completely protect 
against the nephrotoxicity of a 50 mg/kg dose of PAP in F344 rats (Gartland et 
al., 1990).  Other evidence supporting glutathione conjugates as the toxic 
metabolite in vivo, is the finding that biliary cannulation can partially protect 
against nephrotoxicity produced by a 100 mg/kg dose of PAP (Gartland et al., 
1990).  This is significant because glutathione conjugates are known to be 
excreted in the bile where they undergo processing and reabsorption by the GI 
tract.   
For glutathione conjugates to be taken into tubular cells it must first be 
metabolized to the cysteine conjugate.  Two enzymes, gamma-glutamyl 
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 transpeptidase and dipeptidase, located on the brush border of the luminal 
membrane of the nephron are required for this processing (Visarius et al., 1996).  
Work by Trumper et al. (1996) has shown acivicin, an inhibitor of gamma-
glutamyl transpeptidase, protected from APAP-induced renal toxicity in male 
Wistar rats.  Other studies in F344 rats found that administration of acivicin may 
increase the renal toxicity induced by PAP (Fowler et al., 1993; Anthony et al., 
1993).  These findings have not been explained, and there is need for further 
investigation.   
Another unknown topic in the field of PAP nephrotoxicity is the role of 
calcium.  The only published study to mention calcium in PAP toxicity is a study 
by Crowe et al. (1977), which showed that renal mitochondrial calcium increased 
in response to PAP treatment in vivo.    There have been no other studies 
investigating the role of calcium in PAP toxicity.  However, APAP may cause an 
increase in cellular concentrations of calcium within the liver; albeit there are 
conflicting results as to the exact role of calcium in APAP toxicity.  Some studies 
implicate calcium as a critical terminal mediator of APAP toxicity (Corcoran et al., 
1987; Thibault et al., 1991; Deakin et al., 1991; Ray et al., 1993).  Other research 
shows that increases in cellular calcium are a result of terminal APAP toxic 
events and this increased cellular calcium has no effect on APAP toxicity 
(Hardwick et al., 1992; Harman et al., 1992).   
Numerous investigators indicate that ascorbate, an antioxidant, protects 
against PAP toxicity in various animal models.  This protection points to a 
potential oxidative mechanism in the nephrotoxicity induced by PAP (Fowler et 
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 al., 1993; Song et al., 1999; Lock et al., 1993; Hallman et al., 2000).  One 
investigator has found an increase in lipid peroxidation, a measure of oxidative 
stress, in vivo in Wistar rats following PAP treatment (Kanbak et al., 1996).   
Another cellular marker known to be involved in oxidative stress is glutathione.  
Dose-dependent decreases in total glutathione (tGSH) occur with PAP exposure 
both in vivo and in vitro using various animal models (Song et al., 1999; Lock et 
al., 1993; Valentovic and Ball, 1998).  This decrease in tGSH could be 
interpreted as either indicating an oxidative stress mechanism or conjugation of 
reduced glutathione (GSH) with reactive PAP metabolites.  Prior to this research, 
the mechanism of tGSH depletion in PAP toxicity has not been characterized.   
Previous studies have shown that pyruvate (PYR) protects against PAP-
induced toxicity in renal slices from F344 rats (Harmon, 2003).  This observation 
could have two interpretations.  One, PYR could be acting as a substrate for the 
production of ATP to supply the energy for repair mechanisms.  Alternatively, 
PYR could be preventing the oxidative stress induced by PAP.  To date there 
have been no published studies investigating the effects of PYR on PAP-induced 
nephrotoxicity.     
The renal cortical slice model is a well-defined model system for 
evaluation of renal toxicants (Valentovic and Ball, 1998).  Slices provide a 
heterogeneous cell population that maintains the organization of the cortical 
nephron, thus permitting cell-to-cell communication and metabolism.  Previous 
studies in renal cortical slices have shown PAP to be directly toxic, indicating all 
necessary aspects of toxicity are present within the renal slices.  The current 
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 studies have focused on the mechanism of PAP toxicity and PYR protection 
using the renal cortical slice model.   
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 CHAPTER III 
Materials 
Chemicals / Equipment Including Sources  
(Company and catalog number) 
N-acetylcysteine (NAC) (Sigma, A-8199) 
Adenosine-5’-triphosphate (Sigma, A2383) 
Adenosine-5’-diphosphate (Sigma, A-5285) 
Adenosine-5’-monophosphate (Sigma, A-1752) 
p-Aminophenol (Fisher Scientific, O-1184) 
Ascorbic acid (Fisher Scientific, A-61)  
Dextrose (Fisher Scientific, D16) 
5,5’-Dithiobis(2-nitrobenzoic acid)  (Aldrich, D21820-0)  
Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) (Sigma, E-5134) 
Ethylene glycol-bis(β-aminoethlyether)- N, N, N’, N’-tetraacetic acid (EGTA)   
(Sigma, E-4378) 
EGTA-AM (Calbiochem, 324628) 
Glucose oxidase kit (Sigma, 510-A) 
Glutathione disulfide (GSSG) (Sigma, G-6654) 
Glutathione reductase (Sigma, G-3664) 
Lactate dehydrogenase kit (Sigma, 228) 
NADPH (Sigma, N-7505) 
Polyclonal antibody to (E)-4-hydroxynonenal (Alexis Biochemicals, ALX-210-767)   
(kindly provided by K. Kiningham Ph. D.) 
Polyclonal antibody goat anti-rabbit (kindly provided by K. Kiningham Ph. D.) 
Pyruvic acid (Sigma, P-2266)  
Reduced glutathione (GSH) (Sigma, G-6529) 
2-Thiobarbituric acid (Sigma, T-5500)   
2-Vinylpyridine (Aldrich, 13229-2) 
0.45 µm syringe filter (Durapore; Millex-HV) 
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 Radial-pak C18 cartridge (8 mmx10 mm) (Waters Inc.; Milford, Massachusetts). 
Dubnoff metabolic shaker (Precision Scientific; Chicago, IL) 
Sorval MC12V centrifuge 
Guilford Stasar II Spectrophotometer 
Beckman 126 model HPLC 
Precoated TLC plates silica gel 60 F-254 
Biorad transblot apparatus 
BRL vertical gel V-16-2 electrophoresis system 
 
Methods 
Selection of Animal Species and In Vitro Model 
 The male F344 rat animal model was selected for this project because it 
has been shown that these rats have susceptibility to renal toxicants similar to 
that of humans (Kacew et al., 1995).  Previous studies have also shown that p-
aminophenol (PAP) is toxic to this animal model (Valentovic and Ball, 1996; 
Newton et al., 1985).  Male rats were chosen to minimize hormonal variations in 
the model.    
Male F344 rats (200-250 g) were obtained from Hilltop Lab Animals Inc. 
(Scottsdale, PA, USA). Animals were maintained under a controlled ambient 
temperature (21-23oC), humidity (40-55%) and light cycle (lights on 0600-1800 
h). Animals were provided free access to tap water and Purina Rat Chow 
(chunks). All rats were given a minimum 5-day acclimation period prior to 
initiation of any experiments.  This was the only animal model used throughout 
this study. 
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 The renal cortical slice model was used to evaluate PAP toxicity.  This 
was chosen because this model provides a heterogeneous cell population, 
containing proximal tubular cells (the target of PAP toxicity in vivo), that 
maintained the organization of the cortical nephron.  Renal slices allowed cells to 
maintain communication and metabolism.  Furthermore, the in vitro model 
avoided confounding factors such as hemodynamic events that would complicate 
mechanistic evaluations at the cellular level.   
 
Incubation of Renal Slices 
Animals were anesthetized with diethyl ether. The abdominal aorta was 
cut to exsanguinate the animals.  The kidneys were decapsulated, excised, 
quartered, and immediately placed in 5 mL ice-cold Krebs-Ringer buffer kept on 
ice. Renal cortical slices were prepared freehand as described previously 
(Valentovic et al., 1992) and placed in 10 mL ice-cold Krebs-Ringer buffer. The 
slices from one animal were transferred to 5 mL oxygenated Krebs-Ringer buffer 
in a 30-mL beaker. The slices were rinsed two times in 5 mL oxygenated Krebs-
Ringer buffer each for three min at 25oC in an oxygen environment with constant 
shaking (100 cycles/minute) in a gabled Dubnoff metabolic shaker.  The tissue 
(50-100 mg) was evenly distributed in 3 mL of oxygenated Krebs-Ringer in 
designated Erlenmeyer flasks and equilibrated for 10 min at 37oC under 100% 
oxygen and constant shaking (100 cycles/minute). Renal tissue was incubated 
for 30-120 min with a final concentration of 0, 0.10, 0.25, or 0.50 mM PAP in a 
final incubation volume of 3 mL (see Appendix I for preparation of PAP solution). 
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 In some experiments, gluconeogenesis was stimulated by the addition of 
pyruvate (PYR) (100 µL, final bath concentration 10 mM) and incubated for an 
additional 30 min. Media and tissue were collected to measure lactate 
dehydrogenase (LDH) leakage and PYR-stimulated glucose generation.  
 
Effects of Calcium Chelators, Glutathione, Pyruvate, or Ascorbate 
Other experiments required a pretreatment or cotreatment of renal slices 
at 37oC with EDTA, EGTA, EGTA-AM, GSH, NAC, ascorbate, PYR, glucose, or 
vehicle. The durations of pretreatments were 60 min for NAC, 30 or 60 min for 
GSH, 15 or 30 min for EGTA-AM, and 15 min for ascorbate.  EDTA, EGTA, PYR, 
and glucose were added at the beginning of incubations in some experiments.  
Upon completion of the pretreatment period, PAP was added at a final bath 
concentration of 0, 0.10, 0.25, or 0.50 mM.  Tissues were incubated for 30 to 120 
min at 37oC under 100% oxygen and constant shaking (100 cycles/minute).   In 
some experiments, gluconeogenesis was stimulated by addition of 100 µL of 
PYR (10 mM final concentration, in Krebs-Ringer) in the final 30 min of the 
incubation.    
 
LDH and Glucose Assays  
LDH:  Upon completion of incubation, tissues were blotted, weighed and 
added to 10% Triton X-100 in buffer to release tissue LDH.  The amount of LDH 
in the media and tissue was determined using a spectrophotometric kinetic assay 
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 (Sigma, Kit #228).  LDH release into the media was expressed as percent of total 
LDH.   
Gluconeogenesis:  upon completion of incubation, tissues were blotted 
and weighed.  Buffer glucose concentration was measured using a glucose 
oxidase enzymatic assay (Sigma, Kit #510).  Gluconeogenesis was expressed as 
mg glucose per g tissue.   
 
Adenine Nucleotides  
The effect of PAP on adenine nucleotides was evaluated following a 30 
and 60 min exposure to PAP.  Samples were kept on ice at all feasible times to 
prevent degradation.  Upon completion of incubation, renal tissue was blotted, 
weighed and homogenized on ice in 1 mL of Krebs-Ringer buffer. The 
homogenate was vortexed and 500 µL was combined with 250 µL of 3 N 
perchloric acid. The samples were vortexed and allowed to equilibrate on ice for 
five min. The samples were centrifuged for 10 min at 2000 g in a Sorval MC12V 
centrifuge.  A 500 µL aliquot of supernatant was removed and adjusted to pH 7 
with KOH. The samples were vortexed and centrifuged for 10 min at 2000 g.  The 
supernatant was filtered through a 0.45 µm syringe filter.  
The levels of ATP, ADP, and AMP were determined using an HPLC 
method adapted from Lash and Jones (1996). A 100 µL aliquot of sample was 
injected into a Beckman 126 model HPLC with a 100 µL injector loop equipped 
with a Beckman 166 variable wavelength detector.   The mobile phase was a 
gradient of two solutions:  Solvent A:  100 mM potassium phosphate, pH6.0 and 
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 Solvent B: methanol.  The gradient was 7.5 min at 100% A / 0% B; 7.5-minute 
linear gradient to 90% A / 10% B; 15-minute linear gradient to 75% A / 25% B; 
0.5-minute linear gradient to 100% A / 0% B; 10-minute re-equilibration at initial 
conditions.  The flow rate of the mobile phase was 1.3 mL/minute. The column 
was a Radial-Pak C18 cartridge (8 mm x 10 mm). The wavelength for detection 
was 254 nm. ATP, ADP and AMP values were calculated from standard curves 
of ATP, ADP and AMP (0.94 to 9.4 nmol).  Adenine nucleotide levels as low as 1 
nmol could be detected and were linear with respect to the standard curve.  In 
addition, a set of standards was treated as samples to ascertain the extraction 
efficiency.  The efficiency was determined to be approximately 80 %.   
 
Glutathione Determination 
Renal cortical slices (50-100 mg) were incubated with 0, 0.10, 0.25, or 
0.50 mM PAP for 60, 90 or 120 min, as described previously. Tissues were 
weighed and then homogenized in 5 % sulfosalicylic acid in a 1 mL total volume. 
Total glutathione (tGSH) was determined by an enzymatic reaction with 
glutathione reductase using 5,5’-dithiobis(2-nitrobenzoic acid) and NADPH 
(Tietze, 1969; Andersen, 1985).  Glutathione disulfides (GSSG) were measured 
on samples derivatized with 2-vinylpyridine (Griffith, 1980) prior to enzymatic 
measurement of glutathione (nonspecific). Values were expressed as nmol/g 
tissue.  See Appendix I for detailed methods.  
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 Malondialdehyde (MDA)  
Renal cortical slices were prepared and equilibrated as described 
previously. Renal slices were incubated in 3 mL oxygenated Krebs-Ringer buffer 
in an oxygen atmosphere and constant shaking (100 cycles/minute) at 37oC.  
Thiobarbituric acid reactive substances (TBARS) were measured in renal slices 
exposed to 0, 0.10, 0.25, and 0.50 mM PAP for 90 min. The slices were blotted, 
weighed, and homogenized in 1mL Krebs-Ringer buffer. The homogenizer probe 
was rinsed with 1 mL Krebs-Ringer buffer and the sample volume was adjusted 
to 2 mL. A 1.5 mL aliquot of the homogenate was added to an equivalent volume 
of 15% trichloroacetic acid dissolved in 0.25 N HCl.  Protein was precipitated for 
15 min on ice, and the supernatant was collected following centrifugation (2000 g 
at 4oC, 10 min). The supernatant was heated for 15 min at 90oC with an equal 
volume of 0.67% thiobarbituric acid (Ueda and Shah, 1996).  Following a 10 min 
cooling period, the absorbance was measured at 535 nm.  The amount of 
TBARS was calculated based on a standard curve using MDA (0-40 nmol) and 
expressed as nmol TBARS/g tissue. 
 
Protein Determination 
Renal cortical slices were prepared and equilibrated as described 
previously. Renal slices were incubated in 3 mL oxygenated Krebs-Ringer buffer 
in an oxygen atmosphere and constant shaking (100 cycles/minute) at 37oC.   
The slices were blotted, weighed, and homogenized in 1 mL Krebs-Ringer buffer. 
The homogenizer probe was rinsed with 1 mL Krebs-Ringer buffer and the 
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 sample volume was adjusted to 2 mL.  Protein homogenate was stored at –20°C 
until analysis.  Protein concentrations were analyzed as described by Bradford 
(1976).     
 
4-Hydroxynonenal-Adducted Protein  
Renal cortical slices (50-100 mg) were incubated with 0, 0.10, 0.25, or 
0.50 mM PAP for 90 min, as described. Tissues were weighed and then 
homogenized in Krebs-Ringer buffer in a 2 mL total volume.  Western blot was 
used to analyze for the presence of 4-hydroxynonenal (4HNE)-adducted 
proteins.  See Appendix I for detailed methods.  
 
NADPH 
The effect of PAP on NADPH was evaluated following a 60 min exposure 
to PAP.  Samples were kept on ice at all feasible times to prevent degradation.  
Upon completion of incubation, renal tissue was blotted, weighed and 
homogenized on ice in 1 mL of KOH-alcohol.  Homogenate was placed in a 
boiling water bath for 5 min and then allowed to cool on ice for 5 min.  Samples 
were neutralized with 500 µL ice-cold TEA-phosphate buffer and pH adjusted to 
about 7.8.  Samples were vortexed and centrifuged at 10,000 g for 10 min, and 
the supernatant was retained for analysis.  A 100 µL aliquot of 2 mM GSSG was 
added to 1 mL of supernatant, which were allowed to equilibrate to 30°C for 5 
min.  Glutathione reductase was added and change in optical density over time 
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 was measured at 337 nm.  Values were calculated using a standard curve of 
NADPH (Squires et al., 2003; Mallet, personal contact, 2003). 
 
General Toxicity 
Renal slices were prepared as described.  Concentration studies were 
performed in which PAP or vehicle was added, and slices were incubated for 120 
min with PYR present for the final 30 min.  Time-dependent LDH leakage studies 
were conducted such that PAP or vehicle was added to tissue followed by 
incubations for 30, 45, 60, 90 or 120 min.    Separate experiments investigating 
the time-dependent effects of PAP on PYR-stimulated gluconeogenesis were 
conduced where PAP (0, 0.1, 0.25, or 0.5 mM) and PYR or vehicle were added 
and slices incubated for 30, 60, 90, and 120 min.  Glutathione concentrations 
were determined following incubations of renal cortical slices with PAP or vehicle 
for 30 and 60 min.  Adenine nucleotide concentrations were determined following 
incubations of renal cortical slices with PAP or vehicle for 30 or 60 min.   
 
Role of Calcium 
Renal slices were prepared as described.  Extracellular calcium chelators 
EDTA and EGTA were used to investigate the role of Ca++ in PAP-induced 
nephrotoxicity.  Renal slices were added to Krebs-Ringer buffer with or without 
EDTA or EGTA.  PAP or vehicle was added and slices incubated for 120 min.  
PYR was present for the final 30 min to stimulate gluconeogenesis.  In separate 
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 experiments, PAP or vehicle was added to slices, and following a 15 min 
incubation, tissues were transferred to PAP-free Krebs-Ringer buffer with or 
without EDTA or EGTA.  Slices were then incubated for an additional 105 min 
with PYR present for the final 30 min.   
Calcium-free buffer was used to confirm the results of the extracellular 
calcium chelator experiments.  Slices were prepared as described and incubated 
in normal or calcium-free Krebs-Ringer buffer (equal molar Mg++ substituted for 
Ca++).  PAP or vehicle was added and slices incubated for 120 min with PYR 
present for the final 30 min.  Toxicity was assessed in LDH leakage and 
gluconeogenesis studies.   
The intracellular Ca++ chelator, EGTA-AM, was used to investigate the role 
of intracellular calcium in PAP-induced nephrotoxicity.  Renal slices were 
prepared as described.  Slices were preincubated for 15, 30, or 60 min with 
EGTA-AM.  PAP or vehicle was added and slices were incubated for 60 or 120 
min.  In some experiments PYR was present for the final 30 min.  tert-Butyl 
hyrdoperoxide (TBHP) was used as a positive control with similar experimental 
procedures.  Toxicity was assessed in LDH leakage and gluconeogenesis 
studies.   
 
Oxidative Stress 
The role of oxidative stress in PAP toxicity was evaluated using three 
approaches:  glutathione status, 4HNE-adducted protein determinations, and 
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 pretreatments with known oxidative stress modifiers.  Renal slices were prepared 
as described.  PAP or vehicle was added and slices were incubated for 30, 60, or 
120 min.  tGSH and GSSG as percent of tGSH were quantified.   
In separate experiments, PAP or vehicle was added and tissues incubated 
for 90 min.  Following incubations TBARS or 4HNE-adducted proteins were 
analyzed.   
The pretreatment studies incorporated three agents:  GSH, NAC, and 
ACS.  Slices were pretreated with GSH (30 or 60 min), NAC (60 min), or ASC (15 
min).  PAP or vehicle was added and slices were incubated for 60 to 120 min.  
Determinations of LDH leakage and glutathione were performed as described.   
 
Pyruvate Protection 
The role of PYR in PAP toxicity was investigated.  Renal slices were 
prepared as described.  PYR or vehicle and PAP (0, 0.1, 0.25, or 0.5 mM) were 
added and allowed to incubate with renal slices for 30, 60, 90, or 120 min.  LDH 
leakage was determined as described.  Glutathione concentration determinations 
were performed following incubations with renal slices of PYR or vehicle and 
PAP (0, 0.1, or 0.25, mM) for 30 and 60 min.  Adenine nucleotide determinations 
were performed following incubations of renal slices with PYR or vehicle and 
PAP (0, 0.25, or 0.5 mM) for 60 min.  4HNE-adducted proteins were determined 
following incubations of slices with PYR or vehicle and PAP (0, 0.1, or 0.25) for 
90 min.  Each of the above experiments was analyzed as described.  An 
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 alternate energy source, glucose, was used to further characterize the 
mechanism of PYR protection.  Similar experiments were performed where 
glucose was added in lieu of PYR.   
 
Statistical Analyses  
All statistical calculations were performed using SigmaStat software 
package (version 2.03).  Values were reported as mean ± SEM.  Differences 
between groups were analyzed using a repeated-measures analysis of variance 
(RM-ANOVA) followed by a Newman-Keuls test at a 95 % confidence interval 
(Sokal and Rohlf, 1969).  All groups consisted of 4 animals.  
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 CHAPTER IV 
Results 
General Toxicity 
Concentration-response study 
Direct plasma levels of p-aminophenol PAP have not been determined in 
humans exposed to PAP or APAP.  However, assuming similar metabolism in 
humans as in rat models, plasma levels of approximately 0.5 mM PAP should be 
observed in APAP overdose.  The concentrations of PAP selected were 0 to 0.5 
mM.  In this study, PAP was directly toxic to renal cortical slices as noted by LDH 
release and loss of gluconeogenesis (FIGURE 3).  PAP induced both 
concentration- and time-dependent loss of membrane integrity as indicated by an 
increase in the percentage of LDH release.  This effect was observed with 
concentrations as low as 0.10 mM PAP.  PYR-stimulated gluconeogenesis, a 
marker of cell function that is selective for proximal tubular cells, was inhibited at 
all concentrations (0.10, 0.25, and 0.50 mM) of PAP (FIGURE 3).  These studies 
indicated that PAP alters cellular function as measured by PYR-stimulated 
gluconeogenesis and leads to loss of cellular viability as measured by leakage of 
the cytosolic enzyme LDH at concentrations as low as 0.1 mM PAP. 
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 Time-course study 
In order to evaluate a time course for PAP toxicity, incubations were 
conducted for 30-120 min.  PYR-stimulated gluconeogenesis was altered as 
early as 30 min (FIGURE 4).    All evaluated concentrations (as low as 0.1 mM 
PAP) inhibited PYR-stimulated gluconeogenesis, with inhibition being 
concentration-dependent.  The earliest time for the significant increase of LDH 
leakage occurred at 45 min with only the highest concentration of mM PAP 
(FIGURE 5).  The 0.25 mM PAP concentration induced LDH leakage at 60 min, 
while 0.1 mM PAP required 120 min to elevate LDH leakage above control 
(FIGURE 5).  Other studies used shorter incubations with PAP followed by 
transfer of tissue to PAP-free buffer in which incubation continued.  These 
studies showed that 0.25 and 0.5 mM PAP were able to enter tissues within 15 
min and induce LDH leakage, when the tissues were incubated for an additional 
105 min (FIGURE 6).     
 
Adenine Nucleotides 
Another parameter evaluated was the effect of PAP on adenine 
nucleotides.  PAP decreased adenine nucleotides concentrations within 30 min 
(FIGURE 7).  By 60 min, the levels of ATP, ADP and AMP were all decreased in 
the presence of PAP.  In the presence of PAP there was a decrease in the total 
adenine nucleotides, while there was an increase in ATP as percent of total 
adenine nucleotides (FIGURE 8).   
 
 
 
25 
  
 
26 
PAP (mM)
D
L
k
e 
 o
f t
ot
al
)
0
5
10
15
20
25
30
35
40
0 0.10 0.25 0.50
a b
c
d
G
lu
co
se
 (m
g/
g 
tis
su
e)
0.0
1.0
1.5
2.0
bc
a
0 0.10 0.25 0.50
 
 
 
 
0.5b  
 
 
 
(% 
ag 
ea 
H
 
 
 L 
 
FIGURE 3.  Concentration-dependent effect of PAP on PYR-stimulated 
gluconeogenesis and LDH leakage.  Renal slices were incubated with PAP or 
vehicle (DMSO) as described for 120 min with PYR (10 mM) present for the final 
30 min.  Glucose generation was expressed as mg glucose/g tissue.  LDH 
leakage was expressed as percent of total.  Values represent mean ± SEM with 
n=4 animals/group.  Different superscripts indicate a significant difference 
(p<0.05) between treatments.   
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FIGURE 4.  Time-dependent effects of PAP on PYR directed 
gluconeogenesis.  Renal cortical slices were incubated with PYR (10 mM) and 
PAP or vehicle (DMSO) for the designated time period.   Glucose generation was 
expressed as mg glucose/g tissue.  Values represent mean ± SEM with n=4 
animals/group.  Different superscripts indicate a significant difference (p<0.05) 
between treatments within a given time period.     
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FIGURE 5.  Time-dependent effects of PAP on LDH leakage.  Renal cortical 
slices were incubated with PAP or vehicle (DMSO) as described.  Samples were 
collected after designated time period.  LDH leakage was expressed as percent 
of total.  Values represent mean ± SEM with n=4 animals/group.  Different 
superscripts indicate a significant difference (p<0.05) between treatments within 
a given time period.    
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FIGURE 6.  Effect of PAP on LDH leakage following tissue transfer.  Renal 
slices were incubated in Krebs-Ringer buffer for 15 min in the presence PAP or 
vehicle (DMSO).  Tissues were then transferred to Krebs-Ringer buffer in the 
absence of PAP, and incubated as described for an additional 105 min.  LDH 
l akage was expressed as percent of total.  Values represent mean ± SEM with 
n=4 animals/group.  Different superscripts indicate a significant difference 
( <0.05) between treatments.     
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FIGURE 7.  Effect of PAP on individual adenine nucleotides.  Renal cortical 
slices were incubated with PAP or vehicle (DMSO) as described.   Samples were 
collected after designated time period.  Adenine nucleotides were expressed as 
nmol/g tissue.  Values represent mean ± SEM with n=4 animals/group.  An 
asterisk (*) indicates statistical difference (p<0.05) from vehicle treated control 
within given time period.   
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FIGURE 8.  Effect of PAP on adenine nucleotides.  Renal cortical slices were 
incubated with PAP or vehicle (DMSO) as described.  Samples were collected 
after designated time period.  Adenine nucleotides were expressed as total 
adenine nucleotides in nmol/g tissue.  The amount of ATP was expressed as 
percent of total adenine nucleotides.  Values represent mean ± SEM with n=4 
animals/group.  Different superscripts indicate a significant difference (p<0.05) 
within given time period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Role of Calcium 
Role of Extracellular Calcium in PAP toxicity 
The role of extracellular calcium in PAP toxicity was not known.  Previous 
research has shown that increased cellular calcium concentrations were 
necessary for some compounds to manifest toxicity.  Studies were proposed to 
test whether calcium may be involved directly in the toxicity of PAP.  Calcium 
chelators EDTA and EGTA were used to investigate the role of extracellular 
calcium in PAP toxicity.  These compounds are known calcium chelators, having 
a specific affinity for dications.  Both EDTA and EGTA cannot cross cellular 
membranes due to charge.  These compounds can, thus, only chelate 
extracellular calcium.   
 Co-incubation of renal cortical slices with 1.0 mM EDTA or EGTA 
decreased the toxicity of PAP.  Treatment with 1.0 mM EDTA or EGTA 
decreased gluconeogenesis in the absence of PAP (FIGURES 9 and 10).  There 
was no difference between gluconeogenic profiles between groups treated with 
or without EDTA or EGTA (1.0 mM).  However, there was a significant difference 
between EDTA or EGTA and control when compared as percent of control 
(FIGURE 9 and 10).   
 A color change from clear to light red orange was observed when PAP 
was added to buffer in the absence of tissue.  Given that the gluconeogenesis 
studies were recorded at 430 nm, there was a concern that this color change 
may artificially increase glucose determinations.  PAP was added to Krebs-
Ringer buffer without tissue and allowed to incubate under oxygen and constant 
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 shaking at 37°C for 120 min. This buffer was processed like a gluconeogenesis 
sample and absorbance was determined.  The observed absorbances at each 
PAP concentration from this study was subtracted from the EDTA and EGTA 
pretreatment gluconeogenesis study absorbances and values recalculated to 
account for the possible change in absorbance due to the PAP color change 
(TABLE 1).  The calculated glucose concentrations were lower in the background 
subtracted determinations at higher PAP treatments, however, there was minimal 
change in the gluconeogenic profiles between EDTA or EGTA and control groups 
(FIGURES 9 and 10; TABLE 1).   
 The presence of EDTA or EGTA significantly decreased LDH leakage in 
tissues exposed to 0, 0.1, or 0.25 mM PAP (FIGURE 11 and 12).  EGTA was 
better than EDTA at preventing the rise in LDH leakage associated with PAP.   
Studies investigating a potential interaction between EDTA and PAP were 
conducted using thin layer chromatography.  PAP was prepared in Krebs-Ringer 
buffer and Krebs-Ringer buffer containing EDTA.  Aliquots were plated on a thin 
layer chromatography plates (silica gel 60 F-254).  These plates were developed 
with 100% ethyl acetate.  One spot was noted for PAP, which was identical in 
both Krebs-Ringer and Krebs-Ringer with EDTA samples.  There were no other 
spots appreciated.     
Further experimentation was performed to confirm that extracellular EDTA 
or EGTA was acting through chelation of extracellular calcium and not through 
interaction with PAP or a PAP metabolite.  Slices were incubated in the presence 
of PAP or vehicle control for 15 min, followed by transfer of tissues to PAP-free 
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 Krebs-Ringer buffer with or without either EDTA or EGTA where incubation 
continued for 105 min.  The presence of EDTA did not provide protection from 
PAP-induced changes in gluconeogenesis or LDH leakage (FIGURES 13 and 
15).  EGTA (1.0 mM), however, provided protection from PAP-induced changes 
in gluconeogenesis and LDH leakage (FIGURES 14 and 16).  EGTA provided 
complete protection at 0.25 mM PAP and modulation of LDH leakage at 0.5 mM 
PAP.      
 Additional studies addressed the role of extracellular calcium on PAP 
toxicity.  Slices were incubated in the absence of calcium to ensure that 
extracellular calcium could not contribute to toxicity.  Krebs-Ringer was prepared 
in which calcium was replaced with equimolar magnesium.  This substitution 
eliminated the possibility that calcium could be present to induce any effect.  
Decreased gluconeogenesis in the absence of PAP was again seen with 
calcium-free Krebs-Ringer (FIGURE 17).  There was a significant difference 
among gluconeogenic profiles and percent of control between groups treated 
with Krebs-Ringer or calcium-free Krebs-Ringer.  PAP was added to Krebs-
Ringer buffer and allowed to incubate under oxygen and constant shaking at 
37°C for 120 min. This buffer was processed like a gluconeogenesis sample and 
absorbance determined.  The observed absorbances at each PAP concentration 
from this study was subtracted from the gluconeogenesis for calcium-free buffer 
pretreatment studies and values recalculated to account for the possible change 
in absorbance due to the PAP color change (TABLE 2).  The calculated glucose 
concentrations were lower in the background subtracted determinations at higher 
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 PAP treatments; however, there was minimal change in the gluconeogenic 
profiles between Krebs-Ringer and calcium-free Krebs-Ringer groups (FIGURE 
17 and TABLE 2).        
 Results from this study also showed that calcium-free media increased 
LDH leakage in the absence of PAP.  Calcium-free media did not alter the PAP-
induced LDH leakage profile.  However, when compared as percent of control, 
calcium-free media provided protection from PAP-induced LDH leakage 
(FIGURE 18).   
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FIGURE 9.  Effect of EDTA on PAP-induced changes in gluconeogenesis. 
Renal slices were incubated with PAP or vehicle (DMSO) in Krebs-Ringer buffer 
or Krebs-Ringer buffer containing EDTA (1.0 mM) as described for 120 min with 
PYR (10 mM) present for the final 30 min.  Glucose generation was expressed as 
mg glucose/g tissue and percent of control.  Values represent mean ± SEM with 
n=4 animals/group.  Different superscripts indicate a significant difference 
(p<0.05) between treatments.  Asterisk (*) indicates significant difference 
(p<0.05) from vehicle control within each PAP treatment.   
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FIGURE 10.  Effect of EGTA on PAP-induced changes in gluconeogenesis. 
Renal slices were incubated with PAP or vehicle (DMSO) in Krebs-Ringer buffer 
or Krebs-Ringer buffer containing EGTA (1.0 mM) as described for 120 min with 
PYR (10 mM) present for the final 30 min.  Glucose generation was expressed as 
mg glucose/g tissue and percent of control.  Values represent mean ± SEM with 
n=4 animals/group.  Different superscripts indicate a significant difference 
(p<0.05) between treatments.  Asterisk (*) indicates significant difference 
(p<0.05) from vehicle control within each PAP treatment.   
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 (0 mM) 
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(0.25 mM) 
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Ringer 
mg glucose/g 
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 percent of 
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(1.0 mM) 
mg glucose/g 
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mg glucose/g 
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 percent of 
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ABLE 1.  Effect of extracellular calcium chelators, EDTA and EGTA, on 
AP-induced changes in gluconeogenesis (with modification for potential 
bsorbance of PAP).  Renal slices were incubated with PAP or vehicle (DMSO) 
n Krebs-Ringer buffer or Krebs-Ringer buffer containing either EDTA (1.0 mM) or 
GTA (1.0 mM) as described for 120 min with PYR (10 mM) present for the final 
0 min.  Glucose generation was expressed as mg glucose/g tissue and percent of 
ontrol.  Values represent mean ± SEM with n=4 animals/group.  Different 
uperscripts indicate significant difference (p<0.05) between groups.    An asterisk 
*) indicates significant difference (p<0.05) within percent of control from Krebs-
inger control within PAP treatment. 
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F IGURE 11.  Effect of EDTA on PAP-induced LDH leakage.  Renal slices were 
ncubated with PAP or vehicle (DMSO) in Krebs-Ringer buffer or Krebs-Ringer 
uffer containing 1.0 mM EDTA as described for 120 min.  LDH leakage was 
expressed as percent of total and percent of control.  Values represent mean ±
EM with n=4 animals/group.  Different superscripts indicate a significant 
ifference (p<0.05) between treatments.  An asterisk (*) indicates a significant 
ifference (p<0.05) from vehicle control within each PAP treatment.   
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IGURE 12.  Effect of EGTA on PAP-induced LDH leakage.    Renal slices 
ere incubated with PAP or vehicle (DMSO) in Krebs-Ringer buffer or Krebs-
inger buffer containing 1.0 mM EGTA as described for 120 min.  LDH leakage 
as expressed as percent of total and percent of control.  Values represent 
ean ± SEM with n=4 animals/group.  Different superscripts indicate a significant 
difference (p<0.05) between treatments. An asterisk (*) indicates a significant 
ifference (p<0.05) from vehicle control within each PAP treatment.   
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 FIGURE 13.  Effect of EDTA on PAP-induced changes in gluconeogenesis
following tissue transfer.  Renal slices were incubated in Krebs-Ringer buffer 
for 15 min in the presence of PAP or vehicle (DMSO) as described.  Tissues 
were then transferred to Krebs-Ringer or Krebs-Ringer with 1.0 mM EDTA and 
lacking PAP.  The tissue was incubated as described an additional 105 min as 
described.  Glucose generation was expressed as mg glucose/g tissue and 
percent of control.  Values represent mean ± SEM with n=4 animals/group. 
Different superscripts indicate a significant difference (p< 0.05) between 
treatments.   
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FIGURE 14.  Effect of EGTA on PAP-induced changes in gluconeogenesis
following tissue transfer.  Renal slices were incubated in Krebs-Ringer buffer 
for 15 min in the presence of PAP or vehicle (DMSO) as described.  Tissues 
were then transferred to Krebs-Ringer or Krebs-Ringer with 1.0 mM EGTA and 
lacking PAP.  The tissue was incubated as described an additional 105 min as 
described.  Glucose generation was expressed as mg glucose/g tissue and 
percent of control.   Values represent mean ± SEM with n=4 animals/group. 
Different superscripts indicate a significant difference (p< 0.05) between 
treatments.  An asterisk (*) indicates a significant difference (p<0.05) from 
vehicle control within each PAP treatment.  
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FIGURE 15.  Effect of EDTA on PAP-induced LDH leakage following tissue 
transfer.  Renal slices were incubated in Krebs-Ringer buffer for 15 min in the 
presence of PAP or vehicle (DMSO) as described.  Tissues were then 
transferred to Krebs-Ringer or Krebs-Ringer with 1.0 mM EDTA and lacking PAP. 
The tissue was incubated as described an additional 105 min as described.  LDH 
leakage was expressed as percent of total and percent of control.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p< 0.05) between trea
 
 
 
 
 
 
 
 
 
 
 
tments.   
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F IGURE 16.  Effect of EGTA on PAP-induced LDH leakage following tissue 
ransfer.  Renal slices were incubated in Krebs-Ringer buffer for 15 min in the 
resence of PAP or vehicle (DMSO) as described.  Tissues were then 
transferred to Krebs-Ringer or Krebs-Ringer with 1.0 mM EGTA and lacking 
AP.  The tissue was incubated as described an additional 105 min as 
escribed.  LDH leakage was expressed as percent of total and percent of 
ontrol.  Values represent mean ± SEM with n=4 animals/group.  Different 
uperscripts indicate a significant difference (p< 0.05) between treatments.  An 
asterisk (*) indicates a significant difference (p<0.05) from vehicle control withi
t 
 
p 
 
 
P 
d 
c 
 
s 
 
n 
ach PAP treatment.   
 
e 
  
 
45 
 
PAP (mM)
l
g
s
u
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
PAP (mM)
G
lu
co
se
 (%
 o
f c
on
tr
ol
)
0
20
40
60
80
100
120
140
Krebs
Ca++-free Krebs
0 0.10 0.25
c
a
b
c
b
c
0.10 0.25
*
*
 
 
 
 
 
 
e) 
s 
 ti 
/g 
m 
e 
(
 
os 
uc 
G 
 
 
 
 
F IGURE 17.  Effect of calcium-free buffer on PAP-induced changes in 
luconeogenesis.  Renal slices were incubated in Krebs-Ringer buffer or 
alcium-free Krebs-Ringer buffer as described for 120 min with PYR (10 mM) 
resent for the final 30 min.  Glucose generation was expressed as mg glucose/g 
tissue and percent of control.  Values represent mean ± SEM with n=4 
nimals/group.  Different superscripts indicate a significant difference (p< 0.05) 
etween treatments.  An asterisk (*) indicates a significant difference (p<0.05) 
rom vehicle control within each PAP treatment.   
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PAP  
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PAP  
(0.25 mM) 
mg glucose/g 
tissue 
1.314±0.052 a 0.186±0.008 c 0.080±0.006 d Krebs-
Ringer 
percent of 
control 
 14.18±0.61 6.12±0.60 
mg glucose/g 
tissue 
0.405±0.30 b 0.161±0.006 c 0.190±0.021 c Ca++ free 
Krebs-
Ringer percent of 
control 
 40.49±3.83 ∗ 48.17±7.73 ∗ 
T ABLE 2.  Effect of calcium-free buffer on PAP-induced changes in 
luconeogenesis (with modification for potential absorbance of PAP).  Renal 
slices were incubated with PAP or vehicle (DMSO) in Krebs-Ringer buffer or Ca++-
ree Krebs-Ringer buffer as described for 120 min with PYR (10 mM) present for 
he final 30 min.  Glucose generation was expressed as mg glucose/g tissue and 
percent of control.  Values represent mean ± SEM with n=4 animals/group. 
ifferent superscripts indicate significant difference (p<0.05) between groups.   An 
sterisk (*) indicates significant difference (p<0.05) within percent of control from 
rebs control within PAP treatment. 
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IGURE 18.  Effect of calcium-free buffer on PAP-induced LDH leakage. 
enal slices were incubated with PAP or vehicle (DMSO) in Krebs-Ringer buffer 
r Ca++-free Krebs-Ringer buffer as described for 120 min.  LDH leakage was 
xpressed as percent of total and percent of control.  Values represent mean ±
EM with n=4 animals/group.  Different superscripts indicate a significant 
difference (p<0.05) between treatments. An asterisk (*) indicates a significant 
difference (p<0.05) from vehicle control within each PAP treatment.   
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 Role of Intracellular Calcium in PAP toxicity 
 The intracellular calcium chelator EGTA-AM was used to investigate the 
role of intracellular calcium in PAP toxicity.  It is known that EGTA-AM cannot 
bind Ca++ extracellularly, but can penetrate the cell membrane and undergo 
hydrolysis to EGTA.  This intracellular EGTA was thus trapped inside the cell, 
and could bind only intracellular calcium.  Co-incubation of renal cortical slices 
with 0.10 mM EGTA-AM did not significantly alter toxicity of PAP.   
EGTA-AM pretreatment decreased gluconeogenesis in the absence of 
PAP (FIGURE 19).  This data indicated that that calcium aids in the ability of the 
tissue to perform PYR-stimulated gluconeogenesis.  There was no difference 
among gluconeogenic profiles between groups treated with EGTA-AM or vehicle.  
However, there was a significant difference between gluconeogenic profiles 
when compared as percent of control (FIGURE 19).   
PAP was added to Krebs-Ringer buffer without tissue and allowed to 
incubate under oxygen and constant shaking at 37°C for 120 min. This buffer 
was processed like a gluconeogenesis sample and the absorbance was 
measured.  The observed absorbances at each PAP concentration from this 
study was subtracted from the gluconeogenesis for EGTA-AM pretreatment 
studies and values recalculated to account for the possible change in 
absorbance due to the PAP color change (TABLE 3).  The calculated glucose 
concentrations were lower in the background subtracted determinations at higher 
PAP treatments; however, there was minimal change in the gluconeogenic 
profiles between EGTA-AM and vehicle groups (FIGURE 19 and TABLE 3).             
 
 
48 
  The presence of EGTA-AM did not significantly alter PAP-induced LDH 
leakage (FIGURES 20, 21, and 22).  For confirmation, a higher dose of EGTA-
AM (0.2 mM) was used.  Likewise, 0.2 mM EGTA-AM did not decrease PAP-
induced LDH leakage (FIGURES 23 and 24), confirming previous results.   
 tert-Butyl hydroperoxideTBHP was used as a positive control with 0.2 mM 
EGTA-AM.  EGTA-AM (0.2 mM) pretreatment protected against TBHP-induced 
LDH leakage at 30 min, thus confirming the model (FIGURE 25).  Interestingly, 
pretreatment with EGTA-AM did not protect against TBHP toxicity when the 
incubation period was increased to 60 or 120 min, implying that the protection 
provided by EGTA-AM was overcome by further increases in intracellular calcium 
(Harmon, unpublished data).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
  
 
50 
PAP (mM)
G
lu
co
se
 (m
g/
g 
tis
su
e)
0.0
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
PAP (mM)
G
lu
co
se
 (%
 o
f c
on
tr
ol
)
0
10
20
30
40
50
DMSO
0.1 mM EGTA-AM
0 0.10 0.25
c
a
b
c,d
c,dd
0.10 0.25
*
 
 
 
 
 
 
 
 
 
 
 
0.2  
 
 
F IGURE 19.  Effect of EGTA-AM on PAP-induced changes in 
luconeogenesis.  Renal slices were preincubated with 0.1 mM EGTA-AM or 
ehicle (DMSO) for 15 min.  PAP (0, 0.1, or 0.25 mM) was added and slices 
ncubated as described for 120 min with PYR (10 mM) present for the final 30 min. 
lucose generation was expressed as mg glucose/g tissue and percent of control. 
alues represent mean ± SEM with n=4 animals/group.  Different superscripts 
ndicate a significant difference (p<0.05) between treatments. An asterisk (*) 
ndicates a significant difference (p<0.05) from vehicle control within each PAP 
reatment.   
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 T ABLE 3  Effect of EGTA-AM on PAP-induced changes in gluconeogenesis 
with modification for potential absorbance of PAP).  Renal slices were 
preincubated with EGTA-AM or vehicle (DMSO) for 15 min.  PAP or (0, 0.1, or 
.25 mM) was added and slices were incubated as described for 120 min with 
YR (10 mM) present for the final 30 min.  Glucose generation was expressed as 
mg glucose/g tissue and percent of control.  Values represent mean ± SEM with 
n=4 animals/group.  Different superscripts indicate significant difference (p<0.05) 
between groups.   An asterisk (*) indicates significant difference (p<0.05) within 
percent of control from vehicle control within PAP treatment. 
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IGURE 20.  Effect of EGTA-AM (0.1 mM) on PAP-induced LDH leakage (15 
in preincubation with EGTA-AM followed by 60 min incubation).  Renal 
lices were preincubated with EGTA-AM or vehicle (DMSO) for 15 min.  PAP (0, 
.25, or 0.5 mM) was added and slices were incubated as described for 60 min. 
DH leakage was expressed as percent of total and percent of control.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
ignificant difference (p< 0.05) between treatments.    
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FIGURE 21.  Effect of EGTA-AM (0.1 mM) on PAP-induced LDH leakage (60 
min preincubation with EGTA-AM followed by 60 min incubation).  Renal 
slices were pre-incubated with EGTA-AM or vehicle (DMSO) for 60 min.  PAP (0, 
0.25, or 0.5 mM) was added and slices were incubated as described for 60 min. 
LDH leakage was expressed as percent of total and percent of control.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p< 0.05) between treatments.    
 
 
 
 
 
 
 
 
 
 
 
 
53 
  
PAP (mM)
LD
H
 L
ea
ka
ge
 (%
 o
f t
ot
al
)
0
5
10
15
20
a
a
a
a
b
b
0 0.10 0.25
PAP (mM)LD
H
 L
ea
ka
ge
 (%
 o
f c
on
tr
ol
)
0
50
100
150
200
250 DMSO
0.1 mM EGTA-AM
0.10 0.25
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 22.  Effect of EGTA-AM (0.1 mM) on PAP-induced LDH leakage (15 
min preincubation with EGTA-AM followed by 120 min incubation).  Renal 
slices were preincubated with EGTA-AM or vehicle (DMSO) for 15 min.  PAP (0, 
0.1, or 0.25 mM) was added and slices were incubated as described for 120 min. 
LDH leakage was expressed as percent of total and percent of control.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p< 0.05) between treatments.    
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IGURE 23.  Effect of EGTA-AM (0.2 mM) on PAP-induced LDH leakage (30 
in preincubation with EGTA-AM followed by 60 min incubation).  Renal 
lices were preincubated with EGTA-AM or vehicle (DMSO) for 30 min.  PAP (0, 
.25, or 0.5 mM) was added and slices were incubated as described for 60 min. 
DH leakage was expressed as percent of total and percent of control.  Values 
epresent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
ignificant difference (p< 0.05) between treatments.    
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FIGURE 24.  Effect of EGTA-AM (0.2 mM) on PAP-induced LDH leakage (15 
min preincubation with EGTA-AM followed by 120 min incubation).  Renal 
slices were preincubated with EGTA-AM or vehicle (DMSO) for 15 min.  PAP (0, 
0.25, or 0.5 mM) was added and slices were incubated as described for 120 min. 
LDH leakage was expressed as percent of total and percent of control.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p< 0.05) between treatments.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
  
 
57 
 
TBHP (mM)
D
 
l
0
2
4
6
8
10
12
14
16
TBHP (mM)LD
H
 L
ea
ka
ge
 (%
 o
f c
on
tr
ol
)
0
50
100
150
200
250
DMSO
0.2 mM EGTA-AM 
0 0.200.10
*
0.10 0.20
a
b
b
a
a
a,b
 
 
 
 
 
) 
ta 
to 
FIGURE 25.  Effect of EGTA-AM on TBHP-induced LDH leakage.  Renal 
slices were preincubated with EGTA-AM or vehicle (DMSO) for 30 min.  TBHP 
(0, 0.1, or 0.2 mM) was added and slices were incubated as described for 60 
min.  LDH leakage was expressed as percent of total and percent of control. 
Values represent mean ± SEM with n=4 animals/group.  Different superscripts 
indicate a significant difference (p< 0.05) between treatments.   An asterisk (*) 
indicates a significant difference (p<0.05) between vehicle control within TBHP 
treatment.   
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 Oxidative Stress 
Effects of PAP on Glutathione 
 PAP induced a concentration-dependent decrease in total glutathione 
(tGSH) (FIGURE 26).  This effect was both concentration- and time-dependent 
causing depletion of tGSH with 0.25 mM PAP at 30 min and 0.10 mM PAP at 60 
min.  Possibly, the most significant result in this study is that tGSH is nearly 
completely depleted at 120 min following 0.25 mM PAP exposure.  PAP also 
induced an increase in glutathione disulfide (GSSG) as percent of tGSH 
(%GSSG).  There was no significant difference in %GSSG at 30 min; however, at 
60 and 120 min PAP induced an increase in %GSSG (FIGURE 27).  TBHP was 
used as a positive control and induced a decrease in tGSH and an increase in 
%GSSG, confirming the model (Harmon, unpublished data).   
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F IGURE 26.  Time-dependent effects of PAP on total glutathione.  Renal 
ortical slices were incubated with PAP or vehicle (DMSO) as described for 30, 
0 or 120 min.  Total glutathione was expressed as nmol/g tissue.  Values 
epresent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
ignificant difference (p<0.05) from vehicle control within each time period.   
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F IGURE 27.  Time-dependent effects of PAP on glutathione disulfide.  Renal 
ortical slices were incubated with PAP or vehicle (DMSO) as described for 30, 
0, or 120 min.  Glutathione was expressed as percent glutathione disulfide of 
otal glutathione.  Values represent mean ± SEM with n=4 animals/group.  An 
asterisk (*) indicates a significant difference (p<0.05) from control within each 
ime period.   
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 Effects of PAP on 4-hydroxynonenal -Adducted Proteins 
The previous studies suggested that oxidative stress may be an important 
mechanistic step in PAP toxicity.  Evaluation of malondialdehyde (MDA) using 
the thiobarbituric acid (TBA) method was used to investigate further the role of 
oxidative stress.  MDA is a known byproduct of lipid peroxidation, a major 
pathway of oxidative stress.  Contrary to the hypothesis of oxidative stress, PAP 
caused an apparent decrease in detectable MDA (FIGURE 28).  Upon further 
investigation, it was discovered that there is a great deal of debate concerning 
the reliability of the TBA method.  This is in part due to the fact that the TBA 
method measures thiobarbituric acid reactive substances; thus it is an indirect 
measurement.  Studies were then performed to investigate if there was an 
interaction between PAP and the TBA method.  PAP (0.1, 0.25 and 0.5 mM) was 
placed in Krebs-Ringer buffer without tissue with malondialdehyde (MDA) and 
placed under an oxygen atmosphere with constant shaking at 37°C for 90 min.  
This solution was then used in place of the homogenate in the TBA method.  The 
absorbance increased slightly as the concentration of PAP increased.  These 
observations indicate that PAP is not directly interacting with the TBA method.  
The decreases in absorbance of detectable TBA reactive intermediates observed 
thus required PAP to be in the presence of tissue, indicating metabolic activation.   
 Evaluation of 4-hydroxynonenal (4HNE)-adducted proteins was then used 
to investigate the role of oxidative stress in PAP toxicity.  4HNE is a known 
byproduct of lipid peroxidation, and is a direct method analyzing oxidative stress 
(Yamamoto et al., 1987; Goldring et al., 1993; Toyokuni et al., 1994).  4HNE has 
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 also been shown to adduct to proteins.  This increase in 4HNE-adducted proteins 
is associated with an oxidative stress mechanism of toxicity (Uchida et al., 1995).  
Slices were incubated with PAP for 90 min and processed by immunoblot.  The 
presence of PAP induced an increase in 4HNE-adducted proteins (FIGURE 29).  
These increases were most noted at band sizes of 37 kd and 65 kd.   
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 FIGURE 28.  Effect of PAP on thiobarbituric acid reactive substances 
(TBARS).  Renal cortical slices were incubated with PAP or vehicle (DMSO) as 
described for 90 min. TBARS were expressed as malondialdhyde (MDA) 
equivalents nmol per gram tissue.  Values represent mean ± SEM with n=4 
animals/group.  Different superscripts indicate a significant difference (p<0.05) 
between treatments.   
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F IGURE 29.  Effect of PAP on 4HNE-adducted proteins.  Renal slices were 
cubated with PAP or vehicle (DMSO) as described for 90 min.  Following tissue 
olubilization, western blots were performed using an anti-4HNE primary antibody 
with a peroxidase conjugated secondary antibody.  Gels were loaded with same 
oncentration of protein based on mass.  Bands were detected via 
chemiluminescence.    
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 Effects of Pretreatment with Sulfhydryl Containing Compounds 
 The previous results have indicated that oxidative stress does occur in the 
presence of PAP.  Specifically, how did this oxidative stress lead to PAP toxicity?  
Slices were pretreated with sulfhydryl containing compounds to evaluate the 
effect of glutathione (nonspecific) depletion and exogenous sulfhydryl containing 
compounds.  As stated previously, GSH is a tripeptide that is found within cells 
that can act to scavenge oxidative radicals.   Pretreatment of slices with 1.0 mM 
GSH provided protection from LDH leakage in all treatments, including control.  
These data indicate that GSH protects from loss of membrane integrity even in 
the absence of PAP.  GSH did not provide protection against PAP-induced LDH 
leakage expressed as threshold concentration of toxicity or percent of control 
(FIGURE 30 and 31).     
 Given that GSH did not protect against PAP-induced LDH leakage, it is 
possible that the extracellular GSH pretreatment does not increase intracellular 
GSH.  Glutathione levels were determined following 1.0 mM GSH pretreatment 
and subsequent incubation to investigate this concern.  Slices were rinsed in 
Krebs-Ringer buffer prior to quantification to prevent contamination of samples 
with extracellular GSH.  GSH pretreatment caused an increase in tGSH in the 
absence of PAP (FIGURE 32).  This increase in tGSH in response to exogenous 
GSH was overcome by PAP treatment.  Interestingly, tGSH was nearly 
completely depleted despite GSH pretreatment at 0.25 mM PAP.  GSH 
pretreatment did not prevent PAP-induced increases in %GSSG at 120 min 
(FIGURE 33)   
 
 
65 
 NAC, another sulfhydryl compound, may act as a radical scavenger and is 
a known precursor to glutathione.  The concentration of NAC chosen was 0.25 
mM based on studies showing this was the highest concentration that was not 
directly toxic to renal cortical slices (Harmon, unpublished data).  Slices were 
pretreated with 0.25 mM NAC for 15-60 min, followed by incubations in the 
presence of PAP as described.  NAC did not provide protection against LDH 
leakage.  Also, NAC had no effect when compared as percent of control 
(FIGURE 34).   
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F IGURE 30.  Effect of reduced glutathione on PAP-induced LDH leakage (30 
in preincubation with reduced glutathione followed by 90 min incubation). 
Renal slices were preincubated with reduced glutathione or vehicle (H2O) for 30 
in.  PAP (0, 0.25, or 0.5 mM) was added and slices were incubated as 
escribed for 90 min.  LDH leakage was expressed as percent of total and 
ercent of control.  Values represent mean ± SEM with n=4 animals/group. 
ifferent superscripts indicate a significant difference (p< 0.05) between 
treatments.    
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 FIGURE 31.  Effect of reduced glutathione on PAP-induced LDH leakage 
(60 min preincubation with reduced glutathione followed by 90 min 
incubation).  Renal slices were preincubated with reduced glutathione or 
vehicle (H2O) for 60 min.  PAP (0, 0.25, or 0.5 mM) was added and slices were 
incubated as described for 90 min.  LDH leakage was expressed as percent of 
total and percent of control.  Values represent mean ± SEM with n=4 
animals/group.  Different superscripts indicate a significant difference (p< 0.05) 
between treatments.    
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FIGURE 32.  Effect of reduced glutathione on PAP-induced changes in total 
glutathione.  Renal slices were preincubated with reduced glutathione or vehicle 
for 30 min.  PAP (0, 0.1, 02 0.25 mM) was added and slices were incubated as 
described for 120 min.  Total glutathione was expressed as nmol/g tissue.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p< 0.05) between treatments.    
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FIGURE 33.  Effect of reduced glutathione on PAP-induced changes in 
glutathione disulfide.  Renal slices were preincubated with reduced glutathione 
or vehicle for 30 min.  PAP (0, 0.1, or 0.25 mM) was added and slices were 
i cubated as described for 120 min.  The amount of glutathione disulfide was 
expressed as percent of total glutathione.  Values represent mean ± SEM with 
n=4 animals/group.  An asterisk (*) indicates significant difference (p<0.05) from 
vehicle control within GSH treatment.    
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F IGURE 34.  Effect of N-acetylcysteine on PAP-induced LDH leakage.  Renal 
lices were preincubated with N-acetylcysteine or vehicle (H20) for 60 min.  PAP 
0, 0.1, or 0.25 mM) was added and slices were incubated as described for 90 
in.  LDH leakage was expressed as percent of total and percent of control. 
alues represent mean ± SEM with n=4 animals/group.  Different superscripts 
ndicate a significant difference (p< 0.05) between treatments.    
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 Effects of Known Antioxidants and Radical Scavengers 
The previous data have shown that oxidative stress does occur in the 
presence of PAP.  But, is this stress a critical step in PAP toxicity?  Slices were 
pretreated with known antioxidant, ascorbate.  Pretreatment of slices with 2.0 
mM ascorbate provided complete protection from PAP-induced LDH leakage 
(FIGURE 35).   
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F IGURE 35.  Effect of ascorbate on PAP-induced LDH leakage.  Renal slices 
were preincubated with ascorbate or vehicle (H20) for 15 min.  PAP (0, 0.1, or 
.25 mM) was added and slices were incubated as described for 120 min.  LDH 
eakage was expressed as percent of total and percent of control.  Values 
epresent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
ignificant difference (p< 0.05) between treatments.   An asterisks (*) indicate a 
ignificant difference (p<0.05) between vehicle control within each PAP 
treatment.   
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 Pyruvate Protection 
General Toxicity 
  The observation that pyruvate (PYR) protected against PAP-induced LDH 
leakage was made in the process of determining time-dependent alterations in 
gluconeogenesis.  PYR increased both the time and concentration of PAP 
required to induce LDH leakage (FIGURE 36).  The concentration required to 
induce LDH leakage was modulated by the presence of PYR from 0.1 mM to 0.5 
mM, while the time was shifted from 45 min to 90 min.  Coincubation of slices 
with PYR protected against PAP-induced alteration in adenine nucleotide levels.  
PYR provided complete protection from PAP-induced changes in ATP, ADP, and 
total adenine nucleotides, while modulating changes in AMP (FIGURE 37 and 
38).  PYR treatment caused an increase in %ATP at both control and 0.5 mM 
PAP.  This increase likely arised due to PYR being used as an energy source in 
these tissues.  These data show that PYR altered the energetics of slices 
exposed to PAP.   
 Investigations into the mechanism of PYR protection in PAP toxicity were 
conducted using pretreatments with glucose.  Extracellular glucose has been 
shown to be taken into the cell by a facilitated diffusion transporter achieving 
concentrations near that of the media.  The first concentration of glucose (5.55 
mM) was selected because it was a higher energy system than 10 mM PYR.  
The second concentration of glucose was 1.28 mM, which was equal to the 
highest observed glucose concentration with PYR-stimulated gluconeogenesis.  
Glucose (5.55 or 1.28 mM) pretreatment did have minimal protection against 
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 PAP-induced LDH leakage (FIGURE 39 and 40).  However, pretreatment with 
glucose did not provide as much protection as 10 mM PYR.  Glucose 
pretreatment also did not protect against PAP-induced changes in adenine 
nucleotides (FIGURE 41).   
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F IGURE 36.  Effect of PYR on PAP-induced LDH leakage.  Renal cortical 
lices were incubated with PAP or vehicle (DMSO) as described for 60 or 120 
in.  PYR (0 or 10 mM) was present throughout the entire incubation period. 
DH leakage was expressed as percent of total.  Values represent mean ± SEM 
ith n=4 animals/group.  An asterisk (*) indicates statistical difference (p<0.05) 
rom vehicle treated control within each given time period.   
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FIGURE 37.  Effect of PYR on PAP-induced alterations in individual adenine 
nucleotides.  Renal cortical slices were incubated with PAP or vehicle (DMSO) 
as described for 60 min.  PYR (0 or 10 mM) was present for the entire incubation 
period.  Adenine nucleotides were expressed as nmol per gram tissue.    Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
ignificant difference within each adenine nucleotide (p<0.05).   
 
 
 
 
 
s 
 
 
 
 
  
 
78 
 
 
 
PAP (mM)
n
o
e
(n
m
ol
/g
 ti
ss
ue
)
0
100
200
300
400
500
Krebs
10 mM PYR 
0 0.50
a
b
a
a
PAP (mM)
A
TP
 (%
 o
f n
uc
le
ot
id
es
)
0
10
20
30
40
Krebs
10 mM PYR 
0 0.50
a
bb
c
 
 
s  
tid 
cl
e 
in
e 
 N
u 
de 
al
 A 
To
t
 
 
 
 FIGURE 38.  Effect of PYR on PAP-induced alterations in adenine 
nucleotides. Renal cortical slices were incubated with PAP or vehicle (DMSO) as 
described for 60 min.  PYR (0 or 10 mM) was present for the entire incubation 
period.  Adenine nucleotides were expressed as total adenine nucleotides nmol 
per gram tissue and ATP as percent of total adenine nucleotides.    Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p<0.05) between treatments.   
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F IGURE 39.  Effect of PYR or glucose on PAP-induced LDH leakage. 
yruvate (10 mM), glucose (5.55 mM) or vehicle (H2O) was added to renal 
ortical slices, which were incubated with PAP (0, 0.1, or 0.25 mM) as described 
or 120 min.  PYR or glucose was present for the entire incubation period.  LDH 
eakage was expressed as percent of total.  Values represent mean ± SEM with 
=4 animals/group.  An asterisk (*) indicates statistical difference (p<0.05) from 
ehicle treated control.   
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F IGURE 40.  Effect of glucose on PAP-induced LDH Leakage.  Renal slices 
ere incubated with PAP or vehicle (DMSO) as described in Krebs-Ringer buffer 
containing glucose (0.0 or 1.28 mM) for 60 min.  LDH leakage was expressed as 
ercent of total and percent of control.  Values represent mean ± SEM with n=4 
nimals/group.  Different superscripts indicate a significant difference (p< 0.05) 
etween treatments.    
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FIGURE 41.  Effect of glucose on PAP-induced alterations in adenine 
nucleotides.  Renal cortical slices were incubated with PAP or vehicle (DMSO) 
as described for 60 min.  Glucose (0 or 1.28 mM) was present for the entire 
i cubation period.  Adenine nucleotides were expressed as total adenine 
nucleotides nmol per gram tissue and ATP as percent of total adenine 
nucleotides.    Values represent mean ± SEM with n=4 animals/group.  Different 
superscripts indicate a significant difference (p<0.05) between treatments.   
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Effect of PYR on PAP-induced Alteration in Glutathione 
 Studies investigating the effects on PAP-induced changes in glutathione 
were utilized to characterize further the mechanism of protection provided by 
PYR.  PYR caused an increase in tGSH concentrations at all evaluated 
concentrations of PAP.  At 30 min PYR did not significantly protect against PAP-
induced depletion of tGSH (FIGURE 42).  However, the increase in tGSH 
concentrations did maintain tGSH concentrations at normal cellular 
concentrations.   At 60 min, PYR provided protection from PAP-induced depletion 
of tGSH (FIGURE 43).   As indicated in the oxidative stress studies, the presence 
of PAP did not significantly increase %GSSG at 30 min, but induced an increase 
in %GSSG at 60 min.  PYR provided complete protection against PAP-induced 
increases in %GSSG (FIGURE 44 and 45).   
 An alternate energy source, glucose, was used to investigate the 
mechanism of PYR protection of PAP-induced changes in glutathione.  Glucose 
(1.28 mM) did not provide significant protection from PAP-induced depletion of 
tGSH (FIGURE 46).  Glucose prevented PAP-induced increases in %GSSG both 
directly and as percent of control (FIGURE 47).   
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FIGURE 42.  Effects of PYR on PAP-induced alterations total glutathione at 
30 min.  Renal cortical slices were incubated with PAP or vehicle (DMSO) as 
described for 30 min. PYR (0 or 10 mM) was present for the entire incubation 
period.  Total glutathione was expressed as nmol/g tissue.  Values represent 
mean ± SEM with n=4 animals/group.  Different superscripts indicate a significant 
difference (p<0.05) between treatments.   
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F IGURE 43.  Effects of PYR on PAP-induced alterations in total glutathione 
at 60 min.  Renal cortical slices were incubated with PAP or vehicle (DMSO) as 
escribed for 60 min. PYR (0 or 10 mM) was present for the entire incubation 
eriod.  Total glutathione was expressed as nmol/g tissue.  Values represent 
ean ± SEM with n=4 animals/group.  Different superscripts indicate a significant 
ifference (p<0.05) between treatments.   
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FIGURE 44.  Effect of PYR on PAP-Induced alterations in glutathione 
disulfide with 30 min coincubation.  Renal cortical slices were incubated with 
PAP or vehicle (DMSO) as described for 30 min. PYR (0 or 10 mM) was present 
for the entire incubation period.  The amount of glutathione disulfide was 
expressed as percent of total glutathione.  Values represent mean ± SEM with 
n=4 animals/group.  No significant difference was observed.      
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F IGURE 45.  Effect of PYR on PAP-induced alterations in glutathione 
isulfide with 60 min coincubation.  Renal cortical slices were incubated with 
PAP or vehicle (DMSO) as described for 60 min. PYR (0 or 10 mM) was present 
for the entire incubation period.  The amount of glutathione disulfide was 
xpressed as percent of total glutathione.  Values represent mean ± SEM with 
=4 animals/group.  Different superscripts indicate a significant difference 
p<0.05) between treatments.    
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FIGURE 46.  Effects of glucose on PAP-induced alterations in total 
glutathione.  Renal cortical slices were incubated with PAP or vehicle (DMSO) 
as described for 60 min.  Glucose (0 or 1.28 mM) was present for the entire 
incubation period.  Total glutathione was expressed as nmol/g tissue.  Values 
represent mean ± SEM with n=4 animals/group.  Different superscripts indicate a 
significant difference (p<0.05) between treatments.   
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FIGURE 47.  Effect of glucose on PAP-induced alterations in glutathione 
disulfide.  Renal cortical slices were incubated with PAP or vehicle (DMSO) as 
described for 60 min.  Glucose (0 or 1.28 mM) was present for the entire 
i cubation period.  The amount of glutathione disulfide was expressed as 
percent of total glutathione and percent of control.  Values represent mean ±
SEM with n=4 animals/group.  Different superscripts indicate a significant 
difference (p<0.05) between treatments.  An asterisk (*) indicates statistical 
difference (p<0.05) from vehicle treated control within each PAP treatment.   
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 Effect of PYR on PAP-induced Increase in 4HNE-Adducted Proteins 
 PAP treatment caused an increase in 4HNE-adducted proteins that 
indicated an increase in lipid peroxidation and oxidative stress.  Coincubations 
with PYR provided protection from PAP-induced increases in 4HNE-adducted 
protein (FIGURE 48).  This result confirmed the previous results, protection from 
PAP-induced oxidative stress.     
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FIGURE 48.  Effect of PYR on PAP-induced changes in 4HNE-adducted 
proteins.  Renal slices were incubated with PYR or vehicle (H2O) and PAP (0, 
0.1. or 0.25 mM) as described for 90 min.  Following tissue solubilization, 
western blots were performed using an anti-4HNE primary antibody with a 
peroxidase conjugated secondary antibody.  Gels were loaded with same 
concentration of protein based on mass.  Bands were detected via 
chemiluminescence.    
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 Effect of PYR or glucose on PAP-induced alterations in NADPH 
 PAP treatment caused a nonsignificant (p=0.054) decrease in NADPH.    
Coincubations with PYR caused a significant increase in NADPH compared to 
Krebs -Ringer control both in the absence and presence of PAP (FIGURE 49).  
Glucose did not cause a significant increase in NADPH.  However, glucose did 
cause NADPH values to return to Krebs-Ringer control without PAP values.       
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 FIGURE 49.  Effect of PYR or glucose on PAP-induced alterations in 
NADPH.  Renal cortical slices were incubated with PAP or vehicle (DMSO) as 
described for 60 min.  PYR (0 or 10 mM) or glucose (0 or 1.28 mM) was present 
for the entire incubation period.  The amount of NADPH was expressed as 
nmol/g tissue.  Values represent mean ± SEM with n=4 animals/group.  Different 
superscripts indicate a significant difference (p<0.05) between treatments.   
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 CHAPTER V 
 
Summary and Conclusion 
 
General Toxicity 
Previous studies have shown p-aminophenol (PAP) to be toxic to the 
kidney; however the mechanism of PAP toxicity is not well characterized.   The 
goal of this study was to characterize PAP toxicity in a renal cortical slice model 
and to develop a hypothesis to explain the basic mechanism of toxicity.  The 
chosen slice model should serve the purpose by eliminating many confounding 
factors.  In order to make any substantial conclusions about mechanisms, PAP 
toxicity was first characterized in this slice model.  
The concentration of PAP used in this study ranged from 0.1 to 0.50 mM.  
These concentrations were chosen as follows:  the concentration 0.1 mM PAP 
was determined to be the lowest concentration of PAP that could induce LDH 
leakage in this model (Valentovic and Ball, 1998).    Direct plasma levels of PAP 
have not been determined in humans exposed to PAP or APAP.  However, 
assuming similar metabolism in humans as in rat models, plasma levels of 0.5 
mM PAP should be observed in toxic APAP overdose (Newton et al., 1983a).  
Therefore, the 0.50 mM concentration was chosen because of its apparent 
clinical relevance. This approximation may be an underestimate of PAP plasma 
concentrations in humans following APAP overdose, as humans are poor 
acetylators compared to rats.   
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 PAP was directly toxic to renal cortical slices via a concentration- and 
time-dependent mechanism.  PAP produced a concentration-dependent loss of 
membrane integrity as indicated by an increase in the leakage of the cytosolic 
enzyme LDH.  This effect was observed with concentrations as low as 0.10 mM 
PAP.  These results were similar to published results for PAP in the same model 
(Valentovic and Ball, 1998).  PYR-stimulated gluconeogenesis, a marker of cell 
function that is selective for proximal tubular cells, was inhibited at all PAP 
concentrations.  These results were in agreement with earlier studies (Valentovic 
and Ball, 1998).  The concentration studies indicated that PAP altered cellular 
function and increased cellular permeability at concentrations as low as 0.1 mM 
PAP.  PAP also induced toxicity in a time-dependent manner.  PYR-stimulated 
gluconeogenesis was inhibited in a concentration-dependent manner at 
concentrations as low as 0.1 mM PAP.  These data are novel and indicate 
altered cellular function in a concentration-dependent manner within 30 min of 
PAP exposure.    LDH leakage also was significantly increased as early as 45, 
60, and 120 min at 0.50, 0.25, and 0.1 mM PAP, respectively.  The time-
dependent toxicity of PAP was previously reported to occur at 60 min with 0.5 
mM PAP; while other concentrations of PAP have not been studied.  These data 
indicate that PAP causes a concentration- and time-dependent increase in LDH 
leakage.  Other studies showed that incubations as short as 15 min with PAP 
could induce toxicity if allowed to manifest over time.  The present data also 
indicate that PAP enters the tissue within 15 min, where it may remain to induce 
toxicity.  Studies in isolated rabbit proximal tubules have shown PAP-induced 
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 alterations in LDH leakage does not occur until 4 hours with 0.5 mM PAP (Lock 
et al., 1993), which indicates the rat renal cortical slice model is more sensitive 
for the investigation of PAP toxicity.  
Crow et al. (1977) also have shown that PAP caused ultrastructural 
changes in mitochondria isolated from PAP treated rats, which implies the 
mitochondria may be a target of toxicity.  Investigations concerning the effect of 
PAP on mitochondrial function were performed by measuring adenine 
nucleotides.  Such nucleotides are known to be involved in the energetics of a 
cell.  PAP caused depletion of adenine nucleotide concentrations within 30 min.  
By 60 min, the levels of ATP, ADP and AMP were all reduced in the presence of 
PAP.  Interestingly, AMP and ADP were decreased within 30 min, while ATP 
levels were not depleted until 60 min.  If mitochondrial function was a direct 
target of PAP toxicity, ATP concentrations would decrease prior to, or at least 
with decreases in ADP and AMP.  This observation was not made.    The 
depletion of adenine nucleotides occurs prior to loss of membrane integrity as 
measured by LDH leakage, which may indicate that decreases in adenine 
nucleotide concentrations were not due to leakage.  Adenine nucleotides are 
much smaller than the protein LDH, and they may leak through smaller channels 
in the cell membrane.  Further investigation indicated that there is a net decrease 
in total adenine nucleotides with PAP treatment.  The net decrease in adenine 
nucleotides implies that PAP is indeed altering the ability of the cells to sequester 
adenine nucleotides, and that this “loss” occurs prior to loss of membrane 
integrity as measured by LDH leakage.  The altered ability of the slices to 
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 sequester adenine nucleotides could be due either to altered transport systems 
or to leakage from altered membrane integrity.  Further support of adenine 
nucleotide leakage was demonstrated by a significant increase in ATP as percent 
of total nucleotides (%ATP).  These data imply that the decrease in the total 
adenine nucleotides caused a compensatory increase in %ATP to allow the 
tissue to maintain adequate energetics.   The greater decrease in AMP and ADP, 
coupled with the maintenance of ATP levels implies that mitochondrial function is 
sustained with PAP exposure.  It is evident that mitochondrial function is 
maintained even after loss of membrane integrity by the increase in %ATP at 60 
min with 0.5 mM PAP while increased LDH leakage was noted at the same 
concentration of PAP.  The depletion of adenine nucleotides is consistent with 
previous literature (Crowe et al., 1977; Burcham and Harman, 1991; Lock et al., 
1993).  In vivo, studies in female Sprague-Dawley rats have shown PAP to cause 
simultaneous depletion of ATP, ADP and AMP (Shao and Tarloff, 1996).  It is 
significant to note that Sprague-Dawley rats have been shown to have a different 
profile of PAP toxicity, which may account for this difference.   
 
Role of Calcium 
The role of calcium in PAP toxicity is not known.  To date there have been 
no publications investigating the role of calcium in PAP toxicity.  The only 
publication to even mention calcium in PAP toxicity was a study by Crowe et al. 
(1977), which showed that mitochondrial calcium increased in response to PAP 
treatment in vivo.  This increase in mitochondrial calcium in response to PAP 
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 treatment has not been investigated, and is therefore a gap in published 
literature.  Increases in intracellular calcium have been reported to occur in  other 
chemical induced toxicities (Wilson et al., 1984; Orrenius and Nicotera, 1987; 
McCoy et al., 1988).  These increases in cellular calcium concentrations could 
activate phospholipases, proteases and nucleases, all contributing to altered 
cellular function and survival (Orrenius and Nicotera, 1987; Harman and Maxwell, 
1995).  Increases in intracellular calcium occur through one of the following 
mechanisms:  1) release from intracellular stores, including endoplasmic 
reticulum and mitochondria; 2) influx from extracellular space due to altered 
membrane integrity or calcium channels; or 3) diminished export of calcium from 
within the cell.  It was proposed that calcium might be directly involved in the 
toxicity of PAP.  One of the goals of this study was to investigate the role of 
calcium in PAP toxicity.   
 
Role of Extracellular Calcium in PAP toxicity 
The addition of calcium chelators and alterations of extracellular calcium 
have been widely accepted experimental approaches to modulate the in vitro 
toxicity of agents in the investigation of the role of calcium (Thibault et al., 1991; 
Udea and Shah, 1996).  In this study, calcium chelators, EDTA and EGTA, were 
used to investigate the role of extracellular calcium in PAP toxicity.  These 
compounds are known calcium chelators, having a specific affinity for dications.  
Both EDTA and EGTA cannot cross cellular membranes due to charge.  Thus, 
these compounds can only chelate extracellular calcium.   
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  Co-incubation with EDTA or EGTA indicated that EDTA and EGTA 
decreased LDH leakage even in the absence of PAP.  These data indicate that 
extracellular calcium is involved in altering membrane permeability in this in vitro 
model even in the absence of a toxicant.  These observations indicate that 
calcium play a direct role in altered membrane integrity in the renal cortical slice 
model.  The absence of free, extracellular calcium may thus prevent rises in 
intracellular calcium and activation of calcium dependent activation of altered 
membrane integrity.   
 Co-incubation of renal cortical slices with EDTA or EGTA decreased PAP-
induced toxicity.  The presence of EDTA or EGTA significantly decreased LDH 
leakage in tissues exposed to 0, 0.1, or 0.25 mM PAP.  The concentration of 
PAP required to induce LDH leakage was increased in the presence of EDTA as 
well as EGTA.  Also, when comparing as percent of control, EDTA as well as 
EGTA caused a decrease in relative LDH leakage.  The protection afforded by 
EDTA and EGTA indicates that extracellular calcium may have a significant role 
in PAP-induced LDH leakage.  Alternatively, EDTA may directly interact with PAP 
or a toxic metabolite the in media, decreasing the availability of toxic species to 
cause damage. 
Thin layer chromatography was used to investigate the potential 
interaction between the calcium chelators and PAP.  PAP was prepared in both 
Krebs-Ringer and Krebs-Ringer containing EDTA.  Aliquots of the PAP solutions 
were plated on a thin layer chromatography and the plates were allowed to 
develop with ethyl acetate.  The PAP spot was identical for both Krebs-Ringer 
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 and EDTA-Krebs-Ringer.  This indicates that there is no direct binding between 
PAP and EDTA.  Binding of EDTA to a metabolite would require the metabolite to 
be outside the cell, due to the inability of EDTA to cross biological membranes.  
A reactive metabolite would thus have the ability to cause toxicity within the cell 
before exiting the cell in order to bind EDTA or EGTA.  The likelihood of EDTA 
binding to a metabolite is thus an unlikely event.   
 Further confirmation of the role of extracellular calcium in PAP toxicity was 
provided by non-concomitant incubations of tissue with PAP and chelators.  
Slices were incubated in the presence of PAP (0, 0.1, 0.25 mM) for 15 min, 
followed by transfer of tissue to PAP-free buffer with or without EDTA or EGTA 
and incubations continued for 105 min.  In this experiment, PAP was not present 
in the extracellular space while EDTA or EGTA was present; thus preventing any 
interaction between PAP and EDTA or EGTA.  The presence of EDTA did not 
provide protection. However, EGTA (1.0 mM) provided protection from PAP-
induced LDH leakage, giving complete protection at 0.25 mM PAP and 
modulation of toxicity at 0.5 mM PAP.  The protection provided by EGTA 
supports the hypothesis that extracellular calcium plays a direct role in PAP 
toxicity.  This conclusion is also supported by previous literature showing that 
extracellular calcium is directly involved in toxicity with other renal toxicants.  
Groves and others (1990) have shown that cysteine conjugates of some 
haloalkenes induce rises in cellular calcium concentrations that occur prior to 
altered oxygen consumption.  This research has also indicated that chelation of 
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 calcium with EGTA prevented these increases in cellular calcium (Groves et al., 
1990).   
 The chelation experiments also have shown that EGTA provides greater 
protection against PAP-induced LDH leakage.  This can be explained in that 
EDTA chelation of divalent cations is less specific for calcium and binds calcium 
slightly less strongly (Day and Underwood, 1967) (TABLE 4).  EDTA would bind 
other divalent cations like magnesium, thus increasing the effective concentration 
of calcium.  EGTA, on the other hand, is more specific for calcium than other 
divalent cations.  It would bind calcium more strongly and more specifically that 
EDTA, thus leading to a decreased effective calcium concentration relative to 
EDTA.    
TABLE 4.  Log Kabs for EDTA and EGTA 
  EGTA EDTA 
Ca++ 11.0 10.7 
Mg++ 5.4 8.7 
 
Calcium-free media was used to confirm the results of the EDTA and 
EGTA experiments by eliminating the possibility that calcium could be present to 
induce any effect.  There was a significant alteration in PAP toxicity between 
calcium-free Krebs-Ringer and Krebs-Ringer when compared as percent of 
control, thus confirming the data from the EDTA and EGTA experiments.   
Calcium-free media studies indicated that calcium is directly involved in PAP 
toxicity and there is no direct interaction with PAP or a metabolite with EDTA or 
EGTA.   
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 Coincubation with EDTA or EGTA protected against PAP-induced 
changes in PYR-stimulated gluconeogenesis and LDH leakage.  Treatment of 
slices with EDTA, EGTA, or calcium-free media decreased gluconeogenesis in 
the absence of PAP, indicating that altered calcium homeostasis inhibits the cells 
ability to perform PYR-stimulated gluconeogenesis.  There was no difference 
among gluconeogenic profiles between control groups and those treated with 
EDTA, EGTA or calcium-free media.  However, there was a significant difference 
when compared as percent of control.  These data could have two 
interpretations.  First, the lack of extracellular calcium induces a decrease in 
gluconeogenesis in control, causing the apparent increase in percent of control.  
Because the control glucose value is lower in the calcium-depleted groups, there 
might be a false increase in the percent change.  Secondly, calcium chelation 
could be preventing PAP-induced changes in PYR-stimulated gluconeogenesis.  
The lack of calcium decreases the tissues’ ability to perform gluconeogenesis,  
supporting the hypothesis that decreases in control cause an artificial increase in 
percent of control.  However, the calcium-free studies provide evidence that the 
lack of calcium alters the ability of PAP to decrease PYR-stimulated 
gluconeogenesis.  In these studies, glucose concentrations from the calcium-free 
tissues treated with 0.25 mM PAP was significantly increased relative to Krebs-
Ringer control at that PAP concentration. Upon closer evaluation, there is a 
general trend that the calcium-depleted tissue has higher glucose concentration 
when PAP was present than Krebs-Ringer buffer with the same concentration of 
PAP, which implies protection from PAP-induced decreases in gluconeogenesis.   
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 A color change from clear to light red orange was observed when PAP 
was added to buffer in the absence of tissue.  Given that the gluconeogenesis 
studies were recorded at 430 nm, there was a concern that this color change 
may artificially increase glucose determinations.  The potential background 
absorbances were subtracted from the gluconeogenesis for EDTA, EGTA, and 
calcium-free buffer pretreatment studies and values recalculated to account for 
the possible change in absorbance due to the PAP color change (TABLE 1 and 
2).  The changes in glucose concentrations observed between the modified 
glucose determinations and unmodified did not alter the conclusion that PAP-
induced alterations in calcium homeostasis inhibits PYR-stimulated 
gluconeogenesis.  The modifications did decrease the glucose concentrations 
and percent of control determinations.  With knowledge that some degree of PAP 
must enter the tissue, the modified gluconeogenesis determination may be 
greater than actually occurred in vitro.  This modification might thus 
underestimate the ability of calcium chelators and calcium-free media to protect 
against PAP-induced inhibition of PYR-stimulated gluconeogenesis.   
 Further confirmation of the role of extracellular calcium in PAP-induced 
alterations in gluconeogenesis was provided by non-concomitant incubations of 
tissue with PAP and chelators.  The presence of EDTA did not provide 
protection. However, EGTA (1.0 mM) provided protection from PAP-induced 
changes in gluconeogenesis as percent of control.  The protection provided by 
EGTA supports the hypothesis that extracellular calcium plays a direct role in 
PAP toxicity.  These results are also consistent with the LDH leakage studies, 
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 where EGTA but not EGTA protected following tissue transfer.  These results are 
again consistent with the hypothesis that EGTA provides superior chelation of 
extracellular calcium.    This conclusion is also supported by previous literature 
showing that extracellular calcium is directly involved in toxicity with other renal 
toxicants.   
The above experiments have shown that EDTA and EGTA provide 
significant protection against PAP-induced LDH leakage.  These studies imply 
that extracellular calcium has a direct role in the mechanism of PAP toxicity.  
Incubations with PAP in calcium-free Krebs-Ringer buffer confirmed the 
hypothesis that extracellular calcium is involved in PAP toxicity, providing 
protection from PAP-induced LDH leakage.  Further proof that extracellular 
calcium has a direct role in PAP toxicity was provided by studies where slices 
were not treated with PAP and EGTA concomitantly.  EGTA continued to provide 
protection against PAP-induced leakage after tissues were transferred to Krebs-
Ringer buffer with EGTA.  These data provide conclusive evidence that 
extracellular calcium does have a direct role in PAP toxicity.   
 The role of extracellular calcium in PAP toxicity was previously unknown.  
This research has shown that extracellular calcium is directly involved in PAP 
toxicity.  This hypothesis is supported by previous literature showing extracellular 
calcium having a direct role in altered cell function and viability of various  other 
renal toxicants.  Groves et al. (1990) have shown that cysteine conjugates of 
some haloalkenes induce rises in cellular calcium concentrations that occur prior 
to altered oxygen consumption and that chelation of calcium with EGTA 
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 prevented these increases in cellular calcium.  Other studies have demonstrated 
that TBHP and H2O2-induced alteration in membrane integrity was dependent on 
the presence of extracellular calcium (Kim and Kim, 1996).  Finally, Waters et al. 
(1997) have shown that extracellular calcium influx occurs with the mitochondrial 
inhibitor antimycin A and this flux is critical for cell death in renal proximal 
tubules.  The results from this study support the hypothesis that extracellular 
calcium is critical in the toxicity of PAP.   
  
Role of Intracellular Calcium in PAP toxicity 
The intracellular calcium chelator EGTA-AM was used to investigate the 
role of intracellular calcium in PAP toxicity.  It is known that EGTA-AM cannot 
bind Ca++ extracellularly, but can penetrate the cell membrane and undergo 
hydrolysis to EGTA.  This intracellular EGTA is thus trapped inside the cell and 
can bind intracellular calcium.  Co-incubation of renal cortical slices with 0.10 mM 
EGTA-AM did not significantly alter toxicity of PAP at either 60 or 120 min.  The 
presence of EGTA-AM did not significantly decrease LDH leakage at either time 
period.  For confirmation, a higher dose of EGTA-AM (0.2 mM) was used.  Again, 
0.2 mM EGTA-AM did not decrease PAP-induced LDH leakage at either 60 or 
120 min, confirming previous results.  TBHP was used as a positive control with 
0.2 mM EGTA-AM.  EGTA-AM (0.2 mM) did protect against TBHP-induced LDH 
leakage at 30 min, confirming the validity of the model.  This protection from 
TBHP toxicity is consistent with studies in rabbit renal proximal tubules where 
EGTA-AM decreased toxicity of TBHP (Schnellmann, 1991).   
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 The times evaluated for PAP and TBHP were different due to the 
difference in time dependence of the two toxicants.  TBHP is immediately toxic, 
causing an increase in LDH leakage within 30 min.  PAP appears to have a delay 
in toxicity induction as indicated by the PAP-induced LDH leakage time studies.  
This delay in toxicity may be due to the need for activation to some unidentified 
metabolite.  EGTA-AM did not protect against PAP toxicity at any evaluated time 
period, which included apparent PAP toxicity threshold time periods.  The 
inability of EGTA-AM to protect from the toxicity of PAP provides evidence that 
PAP toxicity is not dependent on small rises in intracellular calcium.  
Interestingly, EGTA-AM did not protect against TBHP toxicity when the 
incubation period was extended to 60 or 120 min.  This indicates that EGTA-AM 
can chelate small increases in intracellular calcium concentration.  However, this 
well of chelation may be saturated by further increases in cellular calcium.  The 
EGTA-AM data confirm that small rises in intracellular calcium cannot act as a 
signal for increased membrane permeability.  A hypothesis for the role of calcium 
in PAP-induced alterations in LDH leakage can therefore be made.  PAP induces 
some change in cell function that alters the cellular membranes permeability to 
extracellular calcium.  Calcium can then enter the cell at high concentrations, 
which explains the inability of EGTA-AM to protect.  The increased intracellular 
calcium then activates calcium-dependent pathways that induce changes in 
membrane integrity and cell death.   
 EGTA-AM protected against PAP-induced inhibition of PYR-stimulated 
gluconeogenesis.  The presence of EGTA-AM (0.1 mM) modulated PAP-induced 
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 changes in PYR-stimulated gluconeogenesis when compared as percent of 
control.  There was a general trend that the EGTA-AM treated tissue had a 
higher (nonsignificant) glucose concentration when PAP was present than Krebs-
Ringer buffer with the same concentration of PAP.  Similar background 
subtractions were made for EGTA-AM pretreated gluconeogenesis studies as 
were made for extracellular calcium studies (TABLE 3).  The glucose 
concentration changes observed between the modified and unmodified, again, 
did not alter the conclusion that PAP-induced alterations in calcium homeostasis 
inhibit PYR-stimulated gluconeogenesis.  The background subtraction did 
decrease the glucose concentrations and percent of control determinations. With 
knowledge that some degree of PAP must enter the tissue, the modified 
gluconeogenesis determination may be greater than actually occurred in vitro.  
This modification might thus underestimate the ability of calcium chelators and 
calcium-free media to protect against PAP-induced inhibition of PYR-stimulated 
gluconeogenesis.   
 The significant increases in percent of control in gluconeogenesis 
determinations of calcium-depleted tissues indicate that calcium chelation may 
be preventing PAP-induced changes in PYR-stimulated gluconeogenesis.  A 
conclusion for the role of calcium in PYR-stimulated gluconeogenesis can 
therefore be made.  Calcium appears to play a normal-functioning stimulatory 
role in gluconeogenesis.  However, when cellular concentrations of calcium are 
increased above a threshold level, gluconeogenesis is inhibited.  One 
explanation of these observations is that excessive increases in intracellular 
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 calcium may cause the activation of calcium dependent proteases, which could 
cleave gluconeogenic proteins.  Because both intracellular and extracellular 
calcium chelators provide protection from PAP-induced inhibition of 
gluconeogenesis, the question arises concerning whether the increase in calcium 
concentration is from within the cell or extracellular in origin.  Because 
extracellular calcium has been shown to protect against changes in 
gluconeogenesis and because this extracellular calcium may then enter the cell 
where it may bind EGTA-AM (if present) extracellular calcium appears to be the 
most likely source.   
The overall hypothesis for the role of calcium in PAP toxicity is as follows.  
PAP induces some toxic event that leads to increased membrane permeability to 
calcium.  The influx of calcium from the extracellular space into the cell activates 
calcium dependent enzymes (peptidases, lipases, etc.) which lead to further 
altered cellular function and increased cell membrane permeability.  These 
events then lead ultimately to cell death.   
    
Oxidative Stress 
Effects of PAP on Glutathione 
 As noted previously, reduced glutathione (GSH) is a tripeptide that 
normally functions in cellular protective mechanisms.  It can, however, increase 
toxicity through conjugation, resulting in a more toxic metabolite (Lash and 
Anders, 1987).  Cellular concentrations of glutathione (nonspecific) are altered 
via one of two mechanisms.  One mechanism is the conjugation of GSH with 
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 reactive intermediates through nucleophilic scavenging of electrophiles.  The 
other mechanism is to scavenge radicals, thus converting GSH to the oxidized 
form, glutathione disulfide (GSSG).  Once GSH has been converted to GSSG, it 
can be transported out of the cell, causing depletion of total glutathione (tGSH) 
(Leier et al., 1996; Timbrell, 1991).   
 PAP induced a decrease in tGSH in PAP-treated tissues.  This change 
was both concentration- and time-dependent causing depletion of tGSH, with 
0.25 mM PAP at 30 min and 0.10 mM PAP at 60 min.  Possibly the most 
significant result in this study is that tGSH is nearly completely depleted at 120 
min following 0.25 mM PAP exposure.  This observation provides specific 
evidence that PAP acts to deplete tGSH in both a concentration- and time-
dependent manner to nearly undetectable levels.  Work by Valentovic and Ball 
(1998) has shown that 0.1 mM PAP caused a depletion of tGSH at both 60 and 
120 min.  Other studies have demonstrated that PAP causes a depletion of 
glutathione in various animal models both in vitro and in vivo (Song et al., 1999; 
Shao and Tarloff, 1996; Lock et al., 1993).  In this study, PAP induced an 
increase in GSSG as percent of tGSH (%GSSG).  After 30 min PAP did not 
cause a significant increase in %GSSG.  The p value for %GSSG at 30 min was 
0.061, which is close to significance, indicating this time may be near the 
threshold of change.  At 60 min 0.25 mM PAP induced an increase in %GSSG.  
TBHP was used as a positive control for a known oxidant, confirming the model.  
The increase in %GSSG is a novel observation and suggests that there is some 
degree of oxidative stress occurring with PAP exposure.   
 
 
109 
 Effects of PAP on 4-Hydroxynonelal (4HNE)-Adducted Protein 
The previous studies suggest that oxidative stress may be an important 
mechanistic step in PAP toxicity.  The mechanism of toxicity of PAP was further 
characterized by evaluating the presence of byproducts of oxidative stress.  
Studies evaluating TBARS resulted in an actual decrease in TBARS.  This 
observation was contradictory to the proposed oxidative mechanism of toxicity.  
These results were also in contradiction with previously published increases in 
TBARS in vivo following PAP administration (Kanbak et al., 1996).  Other 
investigators have also observed decrease in TBARS with aromatic amines even 
when oxidative damage is apparent (Valentovic, unpublished data; Rankin, 
unpublished data).  The TBARS method of oxidative stress determination is an 
indirect means of quantifying oxidative byproducts, which allows for potential 
assay interaction.  Evaluation of 4HNE was then used to investigate the role of 
oxidative stress in PAP toxicity.  4HNE is also a known byproduct of lipid 
peroxidation, and is a direct method of oxidative stress determination (Yamamoto 
et al., 1997; Goldring et al., 1993; Toyokuni et al., 1994).  4HNE has also been 
shown to form adducts on proteins.  The increase in 4HNE-adducted proteins is 
associated with oxidative stress mechanism of toxicity (Uchida et al., 1995).  The 
presence of PAP induced an increase in 4HNE-adducted proteins.  These 
increases are best demonstrated at protein molecular weights of 37 kd and 65 
kd.  Evaluations of 4HNE in PAP treated tissue have not been previously 
reported; thus, these observations are novel.  The increase in 4HNE-adducted 
proteins indicate an increase in lipid peroxidation and oxidative stress.  One other 
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 interpretation of these data is that there is an increase in protein at this molecular 
weight.  If PAP could increase the proteins of this molecular weight and these 
proteins were then modified with normal 4HNE adduction, increased band 
intensity would be observed. This concern was investigated using a non-4HNE 
specific protein determination as a function of molecular weight.  It was observed 
that there was actually an overall decrease in protein exposed to PAP; 
specifically bands near 37 and 65 kd were decreased (Harmon, unpublished 
data).  These observations demonstrate that the increase in band intensity with 
4HNE antibody is due to increased presence of 4HNE causing increased protein 
adduction.  The specific bands that are most affected are likely to be membrane 
proteins due to the proximity of these proteins to the site of lipid peroxidation.  
Also these altered proteins may then contribute to the membrane permeability 
transition, allowing cellular contents to leak.  Work is currently being done to 
identify the proteins that are modified both through 4HNE adduction and protein 
concentration in the presence of PAP.   
The glutathione data indicated an oxidative stress mechanism of action.  
The presence of PAP also induced an increase in 4HNE-adducted proteins.  
These data indicate an increase in 4HNE-adducted proteins, thus an increase in 
lipid peroxidation and oxidative stress.   Concentration-dependent decreases in 
tGSH have been previously demonstrated with PAP exposure both in vivo and in 
vitro in various animal models (Song et al., 1999; Lock et al., 1993; Valentovic 
and Ball, 1998).  Prior to this research, however, quantification of %GSSG had 
not been performed and 4HNE had not been investigated.  The increase in 
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 4HNE-adducted proteins and the increase in %GSSG provide conclusive 
evidence that oxidative stress occurs in the presence of PAP.   
 
Effects of Known Antioxidants and Radical Scavengers 
The above data showed that oxidative stress does occur in the presence 
of PAP.  But, is this stress a critical step in PAP toxicity?  To evaluate this 
question, slices were pretreated with a known antioxidant, ascorbate.   Ascorbate 
pretreatment provided complete protection from PAP–induced LDH leakage 
(FIGURE 35).  The complete protection provided by ascorbate showed that 
oxidative stress is a critical step in the mechanism of PAP toxicity.  Protection 
from PAP toxicity by ascorbate implies that PAP is metabolized to a quinone 
imine, which may then redox cycle to produce reactive oxygen species (FIGURE 
51).  Ascorbate most likely prevents the redox cycling of the quinone imine 
metabolite of PAP.    The protection provided by ascorbate is consistent with 
other studies showing protection in the presence of ascorbate.  Coincubation of 
LLC-PK cells with ascorbate decreased PAP-induced decreases in cell viability 
(Hallman et al., 2000).  Lock and associates (1993) also found that ascorbate 
protected against PAP toxicity in isolated rabbit tubules.  In vivo studies in F344 
rats also have shown that ascorbate treatment decreases the toxic effects of 
PAP (Fowler et al., 1993).  Thus, there is conclusive evidence that ascorbate 
protects against PAP toxicity, confirming the direct role of oxidative stress in PAP 
toxicity.    
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FIGURE 51.  Proposed mechanism of PAP-induced oxidative damage 
Effects of Pretreatment with Sulfhydryl Containing Compounds 
 To evaluate the role of glutathione depletion and exogenous glutathione in 
PAP toxicity, slices were pretreated with sulfhydryl containing compounds.  
Pretreatments with GSH for 30 and 60 min followed by 90 min incubation with 
PAP were evaluated.  Pretreatment with 1.0 mM GSH provided protection from 
LDH leakage in all treatments (including control), indicating that GSH protects 
from loss of membrane integrity in this model.  However, GSH did not provide 
protection against PAP-induced LDH leakage as expressed as threshold of 
toxicity or percent of control.  Many studies have indicated that PAP treatment 
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 induces depletion of tGSH, thus GSH may protect through either scavenging 
radicals or conjugation with reactive intermediate.  Hallman et al. (2000) have 
shown that GSH pretreatment prevented PAP-induced decreases in cell viability 
in LLC-PK cells, indicating a protective role in that model.  The inability of GSH 
pretreatment to prevent PAP toxicity in the cortical slice model is a novel result.  
Interpretations as to why GSH did not provide protection could be either 
exogenous GSH cannot increase cellular GSH concentrations or increased GSH 
concentrations are overcome by the mechanism of PAP toxicity.     
 Given that GSH did not protect against PAP-induced LDH leakage, can 
exogenous GSH increase cellular GSH?  The nonspecific protection provided by 
GSH pretreatment supports that exogenous GSH can enter the cell to have an 
effect.  Glutathione levels were determined following 1.0 mM GSH pretreatment 
and subsequent incubation to investigate if exogenous GSH can enter the tissue 
to cause an increase in tGSH.  To prevent extracellular GSH contamination of 
samples, slices were rinsed in Krebs-Ringer buffer prior to isolation.  GSH 
pretreatment caused an increase in tGSH in the vehicle treatment.  This data 
provides conclusive evidence that exogenous GSH can enter tissue to cause an 
increase in cellular GSH.    This increase in tGSH in response to exogenous 
GSH was overcome by PAP treatment.  Interestingly, tGSH was nearly 
completely depleted at 120 min with 0.25 mM PAP despite GSH pretreatment.  
Pretreatment with exogenous GSH was not able to prevent the increase in 
%GSSG induced by PAP.  In fact GSH pretreatment caused a decrease in the 
threshold concentration for PAP to induce a significant increase in %GSSG.  
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 These data explain why exogenous GSH is not capable of preventing PAP 
toxicity.  The exogenous GSH enters the cell, where it encounters the oxidative 
environment caused by PAP or metabolite.  The GSH is then oxidized and 
transported out of the cell as GSSG (Leier et al., 1996; Timbrell, 1991).  
Exogenous GSH, therefore, is capable of increasing tGSH concentrations, but 
PAP-induced oxidative stress depletes the tGSH despite the increased available 
GSH.   
Another sulfhydryl compound, NAC (which may act as a radical scavenger 
and is a known precursor to glutathione), was used as a pretreatment prior to 
PAP exposure.  The concentration of NAC chosen was 0.25 mM based on 
studies showing this was the highest concentration that was not directly toxic in 
the renal cortical slice model (Harmon, unpublished data).  Slices were 
pretreated with 0.25 mM NAC for 15-60 min, followed by incubations in the 
presence of PAP as described.  NAC did not provide protection against LDH 
leakage, and also had no effect when compared as percent of control.  These 
results indicate that NAC is incapable of preventing PAP toxicity.  Alternatively, 
the concentration of NAC may not be sufficient to modulate PAP-induced toxicity.  
NAC being incapable of protecting against PAP toxicity is more likely, given the 
GSH pretreatment results.   
PAP induces oxidative stress as indicated by increased 4HNE-adducted 
proteins and %GSSG.  Pretreatment of slices with GSH provided nonspecific 
decreases in LDH leakage, but did not provide protection against PAP-induced 
LDH leakage.  Also, NAC did not provide protection against PAP-induced LDH 
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 leakage.   This shows that the toxicity of PAP cannot be overcome by sulfhydryl 
containing compounds.  Evaluations of cellular glutathione following GSH 
pretreatment provided an explanation for these observations.   GSH pretreatment 
caused an increase in tGSH in the DMSO vehicle treatment, indicating that the 
exogenous GSH was able to enter the cell.  However, the increase in tGSH was 
less prevalent as the concentration of PAP increased.   At 120 min, 0.25 mM 
PAP caused near complete depletion of tGSH even in the presence of GSH 
pretreatment.  These observations indicate that during PAP toxicity oxidative 
stress causes depletion of cellular glutathione that occurs even in the presence 
of exogenous GSH or other sulfhydryl compounds.   
 
Overall conclusions for general mechanism of PAP toxicity   
An overall conclusion for the role of oxidative stress in PAP toxicity and a 
hypothesis for the mechanism of PAP toxicity can therefore be made (FIGURE 
52).  PAP is taken into the cell and undergoes activation to a reactive 
intermediate, which induces the formation of free radicals.   These radicals cause 
the depletion of cellular glutathione, which occurs even in the presence of 
exogenous GSH or other sulfhydryl compounds.  Once intracellular GSH is 
depleted to a critical level, the reactive oxygen and/or nitrogen species are no 
longer held in check.  The depletion of cellular glutathione causes an imbalance 
between the prooxidants and antioxidants of the cell that allows oxidative 
damage to occur.  This imbalance then causes a cascade of oxidative stress 
including lipid peroxidation, and results in production of 4HNE and 4HNE-
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 adducted proteins.  Damage to membrane phospholipids and proteins triggers an 
increase in membrane permeability to adenine nucleotides and calcium.  The 
loss of membrane integrity leads to loss of total adenine nucleotides causing an 
increase in percent ATP, due to the cell trying to maintain adequate energetics.  
Calcium influx activates calcium dependent enzymes that cause further 
membrane and protein degradation.  These changes result in further decreased 
membrane integrity.   The loss of membrane integrity also allows LDH leakage to 
occur and finally the loss of cell viability.   
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FIGURE 52.  Schema of PAP toxicity 
AXP – adenine nucleotides  
ROS – reactive oxygen species 
RNS – reactive nitrogen species 
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 Pyruvate Protection 
General Toxicity 
 In the process of determining time-dependent alterations in 
gluconeogenesis, the observation that PYR protected against PAP-induced LDH 
leakage was made.  PYR increased both the time and concentration of PAP 
required to induce LDH leakage.  The concentration required to induce LDH 
leakage was changed from 0.1 mM PAP in the absence of PYR to 0.5 mM PAP 
in the presence of PYR.  The time required to induce PAP toxicity was shifted 
from 45 min in the absence of PYR to 90 min in the presence of PYR at 0.5 mM 
PAP.  PYR also protected against PAP-induced inhibition of gluconeogenesis.  
These data indicate that PYR plays a protective role in PAP toxicity.  These 
observations are novel as there are no publications investigating the role of PYR 
in PAP toxicity.  Work by Valentovic and Minigh (2003) have shown PYR to play 
a protective role against myoglobin toxicity in the renal cortical slice model.  
Separate studies have shown that PYR is protective against toxic effects of H2O2 
in myocardial tissue (Mallet et al., 2002).  Finally, PYR has also been shown to 
protect against ischemia reperfusion injury, and that PYR protection was superior 
to glucose protection (Deboer et al., 1993; Tejero-Taldo et al., 1999).  Together, 
these studies support the protective role of PYR in PAP toxicity.   
  The mechanism of PYR protection was further evaluated by determining 
the effects of PYR on PAP-induced changes in adenine nucleotides.  As shown 
in the mechanistic toxicity studies, mitochondrial function is maintained even in 
the presence of PAP.  Coincubation with PYR protected against PAP-induced 
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 alteration in adenine nucleotide levels.  PYR provided complete protection from 
PAP-induced changes in ATP, ADP, and total adenine nucleotides, while 
modulating changes in AMP.  PYR treatment did cause an increase in %ATP at 
both control and 0.5 mM PAP, which likely arises due to PYR being used as an 
energy source in these tissues.   
 Slices were coincubated with glucose as an alternate energy source to 
investigate further the role of PYR protection of PAP toxicity.  Previous studies 
have found that the basolateral membrane of the proximal tubule has a sodium-
independent glucose transporter (Silverman, 1986; Mullin et al., 1989).  This 
transporter is a facilitated diffusion transporter that has been shown to carry 
glucose both into and out of the cell.  Therefore, glucose would be taken into the 
proximal tubular cells at concentrations near that of extracellular space.  In this 
study, glucose concentrations selected were 5.55 mM and 1.28 mM.  The 5.55 
mM glucose concentration was selected because this was a higher energy 
system than 10 mM PYR, given that for every molecules of glucose added 2 
molecules of PYR are produced with additional energy.  Also studies by 
Valentovic and Ball (1998) have shown that addition of the alternate 
gluconeogenic substrate, glucose-6-phosphate (10 mM) caused a greater than 
seven fold increase in glucose levels when compared to 10 mM PYR.  Adding 
higher glucose concentrations would therefore be in excess, skewing any 
interpretation of results.    The 1.28 mM glucose concentration was selected in 
that this was the highest concentration of glucose attained following 120 min 
PYR-stimulated gluconeogenesis with 10 mM PYR.   
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  Glucose coincubations (5.55 and 1.28 mM) did provide minimal protection 
against PAP-induced toxicity.  Protection from PAP-induced LDH leakage was 
observed following glucose coincubation.  However, glucose did not provide as 
much protection as 10 mM PYR.  Glucose coincubation also did not protect 
against PAP-induced depletion of adenine nucleotides.  These data indicate that 
PYR is superior to glucose as a cytoprotectant and that the availability of 
energetic substrate cannot account fully for protection provided by PYR.  This 
observation is consistent with previous literature where Deboer et al. (1993) has 
shown that PYR and glucose together provided greater protection than glucose 
alone in myocardial ischemia reperfusion injury.  Greater protection provided by 
PYR may thus be explained due to superior prevention of oxidative stress 
induced by PAP.   
  
Effect of PYR on PAP-induced Alteration in Glutathione 
 The effects on PYR on PAP-induced changes in glutathione were 
evaluated to further investigate the mechanism of protection provided by PYR.  
PYR caused an increase in tGSH concentrations both at 30 and 60 min at all 
evaluated concentrations of PAP.  These findings are consistent with literature 
published by Valentovic and Minigh (2003) in which PYR coincubation caused an 
increase in tGSH at 120 min in renal cortical slices.  These findings could have 
two possible explanations.  One is that PYR may act to increase de novo 
synthesis of GSH.  The other explanation is that PYR is keeping glutathione in 
the reduced state.  The decrease in the availability of GSSG for its transporter 
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 may prevent efflux of glutathione from the tissue (Leier et al., 1996; Timbrell, 
1991).  The latter is a more reasonable explanation due to the time needed to 
begin de novo synthesis (Visarius et al., 1996).  Regardless of cause, PYR 
induces an increased intracellular concentration of tGSH.   
 PYR also protected from PAP-induced depletion of glutathione.  As noted 
previously PAP induces a time- and concentration-dependent decrease in tGSH, 
beginning at 30 min.  At 30 min, PYR did not significantly protect against PAP-
induced depletion of tGSH (FIGURE 39).  However, the increase in tGSH 
concentrations in the presence of PYR did maintain tGSH concentrations at 
normal concentrations.  At 60 min, PYR provided protection from PAP-induced 
depletion of tGSH.   Finally, PYR provided complete protection against PAP-
induced increases in %GSSG at 60 min.  These observations are consistent with 
other studies showing PYR protection from effects of other toxicants by 
maintaining tGSH concentrations and the ratio of GSH to GSSG (Valentovic and 
Minigh, 2003; Mallet et al., 2002).  The above data provide conclusive evidence 
that PYR causes the maintenance of glutathione at or near normal 
concentrations.  PYR prevents oxidative stress induced by PAP, maintaining 
glutathione in the reduced state.   
 There are three pathways through which a compound may act to prevent 
oxidative stress.  First, it could prevent the formation of the reactive intermediate.  
Second, it could scavenge the reactive intermediate.  Third, a substance may 
provide the needed substrate for the recycling of normal protective mechanisms.  
The major cellular protective mechanism for prevention of oxidative stress is 
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 through recycling glutathione (FIGURE 53).  Following exposure to an oxidant 
GSH is converted to GSSG.  This GSSG is no longer functional in the cell and is 
either recycled to GSH or transported out of the cell (Leier et al., 1996; Timbrell, 
1991).  As indicated previously, PYR causes an increase in tGSH, likely due to 
the recycling of GSSG.  These observations imply that PYR may exert its 
protection by recycling glutathione.   
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FIGURE 53.  Glutathione recycling.  
ROS – reactive oxygen species  
Effect of PYR on PAP-induced Increase in 4HNE-Adducted Proteins 
Evaluation of 4HNE-adducted proteins in the presence of PYR was then 
used to confirm the role of PYR in the prevention of oxidative stress induced by 
PAP.  As noted previously, the presence of PAP induced an increase in 4HNE-
adducted proteins, thus indicating an increase in lipid peroxidation and oxidative 
stress. Coincubation with PYR caused a decrease in the intensity of the bands 
where the increase in 4HNE-adduction of protein in the presence of PAP had 
been detected.  These decreases in intensity provided evidence that PYR 
prevented PAP-induced increases in 4HNE-adducted proteins.  This prevention 
confirms the hypothesis and provides conclusive evidence that PYR prevents of 
oxidative stress induced by PAP.   
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Effect of Glucose on PAP-induced Alteration in Glutathione 
 The alternate energy source glucose was used to investigate the 
mechanism of pyruvate (PYR) protection of PAP-induced changes in glutathione.  
Glucose (1.28 mM) did not provide significant protection from PAP-induced 
depletion of tGSH. Glucose also did not provide a significant increase in tGSH at 
control or any concentration of PAP.  These data indicate that glucose cannot 
cause an increase in concentrations of tGSH and cannot prevent PAP-induced 
depletion of tGSH.  This implies that glucose cannot act either to provide de novo 
synthesis of GSH or to keep the concentration of GSSG reduced to a significant 
level to prevent transport out of the tissue.   
 Glucose did not completely prevent PAP-induced increases in %GSSG; 
but did modulate the increase when expressed as percent of control.  These data 
imply that glucose also acts to prevent the oxidative stress induced by PAP, thus 
keeping glutathione in the reduced state.  Glucose appears to be protecting 
against increases in %GSSG through the recycling of GSSG to GSH.  With the 
knowledge that this recycling requires a NADPH-dependent pathway, it appears 
that glucose is acting as a substrate for the pentose phosphate pathway 
(FIGURE 54), which is a major NADPH production pathway for cells (Winiarsha 
et al., 2003).   
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FIGURE 54.  Pentose phosphate pathway  PYR 
 
The ability of glucose to modulate the increase in %GSSG confirms the 
hypothesis that PYR protects against PAP-induced oxidative stress in part 
through recycling GSSG.  Additional evidence for this pathway of protection was 
provided by studies in LLC-PK cells in which pretreatment with NADPH provided 
protection from PAP-induced toxicity (Hallman et al., 2000).  The protective 
effects of NADPH in PAP toxicity indicate that enhancing glutathione recycling 
can prevent PAP toxicity.    
  As noted previously PYR also increases tGSH concentrations.  However, 
glucose pretreatment did not cause an increase in tGSH.  Glucose also did not 
provide the same degree of protection from increased %GSSG as PYR, even 
though the concentration of glucose is much higher than seen by the tissue in the 
presence of PYR.  PYR must be providing enhanced reducing power either 
through ease of metabolism through the pentose phosphate pathway or via some 
alternate NADPH producing pathway.   
 Glucose must be phosphorylated by hexokinase prior to entering the 
pentose phosphate pathway, which creats a barrier to NADPH production.  PYR-
stimulated gluconeogenesis is also an energy dependent pathway, requiring 6 
ATP per molecule of glucose formed (FIGURE 55).  PYR should not be a more 
readily usable substrate for the pentose phosphate pathway as compared to 
glucose.  Also, the concentration of glucose used in the previous studies was 
much higher than the tissues actually encounter because the slices must make 
glucose from PYR.  In actuality, vehicle treated slices begin the incubation near 0 
mM glucose at time zero.  By 30 min, concentrations of glucose in the media 
have risen to only 0.45 mM, and at 60 min concentrations of glucose have 
reached about 0.8 mM.  Treated tissues encounter even less glucose; therefore, 
the concentration of glucose in PYR treated tissue is much lower than that of the 
1.28 mM glucose pretreatment.  PYR must be acting to prevent oxidative stress 
through an alternate pathway.   
 PYR may also be used as a substrate for pyruvate dehydrogenase and 
subsequently the Krebs cycle (FIGURE 55).  Previous literature has shown that 
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 the kidney has a high concentration of NADP+ dependent isocitrate 
dehydrogenase (Haraguchi et al., 2003).  Studies by Robertson in cardiac tissue 
have shown that the isocitrate dehydrogenase pathway provides a significantly 
greater ability to reduce GSSG than the pentose phosphate pathway (Robertson 
et al., 1997).  This pathway provides an alternate means with which PYR may 
provide NADPH for glutathione recycling.  Previously published studies support 
this pathway of protection.  Deboer et al. (1993) have shown that PYR and 
glucose together provide greater protection than glucose alone in myocardial 
ischemia reperfusion injury.  Other research has shown that PYR and 
acetoacetate also provide protection in stunned myocardium.  This protection 
appears to be dependent on activation of Krebs cycle pathways (Tejero-Taldo et 
al., 1999; Squires et al., 2003).  This pathway may explain the enhanced 
protection in the presence of PYR compared to glucose.   
 Results from these studies can be used to formulate an overall hypothesis 
for protection provided by PYR.  PYR protects through increasing tGSH 
concentrations and recycling of GSSG to GSH, thus maintaining the balance of 
antioxidants to prooxidants and preventing oxidative stress.  PYR may also act to 
prevent oxidative stress through either prevention of redox cycling or directly 
scavenging reactive oxygen species.  Further research is needed to characterize 
the roles of these pathways in PYR protection.     
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FIGURE 55.  Pathways for PYR-stimulated production of NADPH 
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 Effect of PYR and glucose on NADPH 
Previous studies have indicated that PAP protects through NADPH-
dependent recycling of glutathione.  These studies have implied this means of 
protection through indirect measurements of NADPH by evaluating effects.  
Finally, the effects of PAP on NADPH and the effects of PYR and glucose on 
potential PAP-induced changes in NADPH was evaluated.  PAP caused a 
decrease (nonsignificant p=0.054) in NADPH in the absence of PYR or glucose, 
indicating that PAP may deplete NADPH.  PYR but not glucose caused a 
significant increase in NADPH over control both with and without PAP.  This 
increase in NADPH confirms that PYR can increase NADPH, thus supplying the 
reducing potential for glutathione recycling.  It was also significant to note that 
glucose in the presence of PAP did increase (nonsignificantly) NADPH back to 
control without PAP values.  These results provide an explanation of how 
glucose provides moderate protection from PAP toxicity.  Finally, it is also 
significant to note that neither PYR nor glucose caused a significant increase in 
NADPH relative to control in the absence of PAP.  These results imply that cells 
possess some means of recognizing oxidative stress, and shunting energetic 
substrates (specifically PYR) to the production of NADPH.     
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 Summary of PYR Protection 
 PYR provided protection against PAP-induced increases in LDH leakage.  
PYR increased both the time and concentration of PAP required to induce LDH 
leakage.  PYR also protected against PAP-induced alteration in gluconeogenesis 
and adenine nucleotide levels.  These data indicate PYR plays a protective role 
in PAP toxicity.  Pretreatment with an alternate energy source, glucose, at higher 
energy availability did not provide as much protection as 10 mM PYR.  These 
data imply that the availability of energy cannot fully account for protection 
provided by PYR. Therefore, prevention of oxidative stress may account for this 
protection.  PYR caused an increase in tGSH concentrations as well as 
prevention of PAP-induced depletion of tGSH.  PYR also provided complete 
protection against PAP-induced increases in %GSSG.  Finally, PYR also 
prevented PAP-induced increases in 4HNE-adducted proteins, confirming the 
hypothesis that PYR is protecting against PAP toxicity by prevention of oxidative 
stress.  These data provide conclusive evidence that PYR is indeed preventing 
oxidative stress induced by PAP.    
 The mechanism through which PYR prevents this oxidative stress was 
further delineated through studies with the alternate energy source glucose.  
Glucose did provide protection from increases in %GSSG, which implies 
NADPH-dependent recycling of glutathione.  PYR, however, provided greater 
protection from increases in %GSSG and caused an increase in tGSH, indicating 
an alternate pathway.  PYR has also been shown to cause a significant increase 
in NADPH that is superior to glucose.  PYR likely increases NADPH through the 
 
 
129 
 isocitrate dehydrogenase pathway, which has been shown to be superior to the 
pentose phosphate pathway, explaining the superior protection of PYR.      
 From these results an overall conclusion for protection provided by PYR 
can be formulated (FIGURE 56).  PYR protects by increasing tGSH 
concentrations and recycling of GSSG to GSH through a NADPH-dependent 
pathway, therefore, maintaining the balance of antioxidants to prooxidants and 
preventing oxidative stress.   
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FIGURE 56.  Schema of PYR protection from PAP toxicity 
AXP – adenine nucleotides  
ROS – reactive oxygen species 
RNS – reactive nitrogen species 
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 Future Studies 
The current study addressed many aspects of PAP toxicity in the renal 
cortical slice model, which can be extrapolated to APAP nephrotoxicity.  
However, the current study also raises additional questions concerning PAP 
toxicity in this model and in vivo.  These questions, as well as future studies to 
address them, are discussed as follows. 
As indicated by studies in cardiac tissue, isocitrate dehydrogenase has a 
greater ability to reduce GSSG than the pentose phosphate pathway (Robertson 
et al., 1997).  Also, rat kidney has been shown to highly express isocitrate 
dehydrogenase (Haraguchi et al., 2003).  These two observations provide a 
mechanistic explanation of how PYR reduces oxidative stress.  To confirm this 
hypothesis, determinations of isocitrate dehydrogenase and the pentose 
phosphate pathway reducing potential in the renal cortex could be investigated.  
The renal cortex of F344 rats would be homogenized and centrifuged at 10,000 
G.  The pellet would be resuspended for further analysis.  GSSG (90 µM) and 
NADP+ (14 µM) would be added followed by the addition of glucose, PYR, 
glucose-6-phosphate (substrate for glucose-6-phosphate dehydrogenase, the 
first step in the pentose phosphate pathway), or isocitrate (substrate for isocitrate 
dehydrogenase).  Results would indicate the relative reducing potential of each 
substrate and thus each pathway.   
As indicated by the 4HNE studies, proteins were altered in the presence of 
PAP causing the formation of protein adducts.  There were specific proteins that 
were altered to a greater extent.  Identification of which proteins are altered may 
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 provide specific evidence for further characterization of mechanistic toxicity.  This 
research could also investigate proteins and enzymes that are altered through 
modification or overall expression.  Work is currently being done to identify 
proteins altered in the presence of PAP, both through 4HNE adduction and 
altered protein concentration.    
 The focus of this research was to identify the mechanism of toxicity of 
PAP in the in vitro model.  Previous in vivo research on PAP toxicity has implied 
that PAP may be first converted to a glutathione conjugate and then to a cysteine 
conjugate (Fowler et al., 1991; Klos et al., 1992).  The question must then be 
posed, is the mechanism of toxicity for PAP and the cysteine conjugate of PAP 
(cys-PAP) similar?  To investigate this, the cys-PAP may be used in an in vitro 
model system.  Due to the lack of luminal access in the cortical slice model and 
to the mechanism of cysteine conjugate transport via the luminal brush boarder 
membrane, an alternate model must be used.  One reasonable model for these 
studies would be freshly isolated proximal tubular cells from F344 rats.  Isolated 
cells would be treated with PAP, cys-PAP, or vehicle in parallel, followed by 
determination of toxicity similar to studies in the cortical slice model.     
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 Appendix:  Detailed Methods 
Buffer Preparation 
Krebs-Ringer buffer (126.4 mM NaCl; 6.0 mM Na2HPO4; 5.2 mM KCl; 1.3 
mM MgSO4; 1.0 mM CaCl2) 
 Into approximately 900 mL of deionized distilled water, the following 
salts were added:  7.39 g NaCl; 852 mg Na2HPO4; 385 mg KCl; 
318 mg MgSO4; 149 mg CaCl2.  The pH was adjusted to 7.4 with 
HCl.   The volume was brought to 1 L with deionized distilled water, 
followed by a final pH check.  Prior to incubation the buffer was 
oxygenated for 45 min. 
Calcium-Free Krebs-Ringer buffer (126.4 mM NaCl; 6.0 mM Na2HPO4; 5.2 
mM KCl; 1.3 mM MgSO4; 1.0 mM MgCl2) 
Into approximately 900 mL of deionized distilled water, the following 
salts were added:  7.39 g NaCl; 852 mg Na2HPO4; 385 mg KCl; 
318 mg MgSO4; 203 mg MgCl2.  The pH was adjusted to 7.4 with 
HCl.   The volume was brought to 1 L with deionized distilled water, 
followed by a final pH check.   Prior to incubation the buffer was 
oxygenated for 45 min. 
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 Phosphate buffer for HPLC 
Into approximately 900 mL of deionized distilled water, 13.6 g KPO4 
was dissolved.  The pH was adjusted to 6.0 with HCl and KOH.  
The volume was brought to 1 L with deionized distilled water, 
followed by a final pH check.  The buffer was filtered through a 
Millipore pre-filter (AP15, 47 mm).      
 
Compound Preparation 
ACS 
Ascorbic acid (ascorbate) (32.2 mg) was dissolved in 1 mL H20, 
yielding 200 mM ascorbate.  A 30 µL aliquot was added to 3 mL of 
incubation buffer to yield a final concentration of 2 mM.   
PAP 
p-aminophenol (PAP) (5.5 mg) was dissolved in DMSO and 
brought to 1 mL, yielding 50 mM PAP. A 1:2 dilution and 1:5 dilution 
were made with DMSO of the stock PAP to yield 25 mM and 10 
mM, respectively.  A 30 µL aliquot of each concentration was added 
to 3 mL of incubation buffer to yield a final concentration of 0.50, 
0.25 or 0.10 mM, respectively.     
EDTA 
EDTA (18.7 mg) was dissolved in 50 mL Krebs-Ringer buffer, 
yielding 1 mM EDTA Krebs-Ringer buffer.  The buffer was then 
oxygenated parallel to EDTA free Krebs-Ringer buffer.   
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 EGTA 
EGTA (18.7 mg) was dissolved in 50 mL Krebs-Ringer buffer, 
yielding 1 mM EGTA Krebs-Ringer buffer.  The buffer was then 
oxygenated parallel to EGTA free Krebs-Ringer buffer.  
 
EGTA-AM 
EGTA-AM (10 mg) was dissolved in 1 mL DMSO.  A 20 µL or 40 µL 
aliquot was added to 3 mL of incubation buffer to yield a final 
concentration of 0.1 mM  or 0.2 mM, respectively. 
GSH 
Reduced glutathione (GSH) (30.7 mg) was dissolved in 1 mL H20, 
yielding 100 mM GSH.  A 30 µL aliquot was added to 3 mL of 
incubation buffer to yield a final concentration of 1.0 mM.   
 
KOH-alcohol 
KOH (2.8 g) was dissolved in 100 mL of 50:50 ethanol and H2O  
NAC 
N-acetylcysteine (NAC) (16.3 mg) was dissolved in 1 mL H20, 
yielding a 100 mM solution of NAC.  The stock was diluted to 25 
mM NAC.  A 30 µL aliquot was added to 3 mL of incubation buffer 
to yield a final concentration of 0.25 mM.   
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 PYR 
Pyruvate (PYR) (165 mg) was dissolved in 5 mL oxygenated Krebs-
Ringer buffer.  A 100 µL aliquot was added to 3 mL of incubation 
buffer to yield a final concentration of 10 mM.   
TBHP 
tert-Butyl hydroperoxide (TBHP), 70% in H20, (12.9 µL) was 
dissolved in 1 mL H20, yielding a 100 mM solution of TBHP.  A 1:5 
dilution and 1:10 dilution were made of the 100 mM TBHP to yield 
20 mM and 10 mM, respectively.  A 30 µL aliquot of each TBHP 
concentration was added to 3 mL of incubation buffer to yield a final 
concentration of 1.0, 0.20 or 0.10 mM, respectively.     
TBA 
2-Thiobarbituric acid (TBA) (167 mg) was dissolved in 25 mL of 
water.  The flask was wrapped in foil and warmed to ~90oC until 
dissolved.   
TEA-phosphate buffer 
triethanolamine hydrochloride (TEA) (9.3 g),  KH2PO4 (5.44 g), and   
K2HPO4  (1.74 g)   was dissolved in 100 mL H20,  
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 Glutathione  Determination 
Total glutathione (tGSH) levels were measured based on the methods of 
Anderson (1985).  Following incubation, the tissues were rinsed in 3 mL of 
Krebs-Ringer buffer, blotted and weighed.  Once weighed, the tissues were 
placed in 500 µL of 5% sulfosalycilic acid and homogenized followed by a rinse 
of the homogenizer shaft with an additional 500 µL of 5% sulfosalycilic acid.  The 
mixture was centrifuged at 9000 g for 10 min at 4°C.  The supernatant was 
decanted and saved.  For tGSH levels, 25 µL of supernatant was combined with 
175 µL water and 700 µL of 0.3 mM NADPH.  Following a 10-minute incubation 
at 30 °C, 100 µL of 6 mM DTNB and 100 µL of glutathione reductase (16 
units/mL) were added.  The samples were placed immediately into the 
spectrophotometer set at 412 nm and the absorbance was read at 0, 15, 30, 60, 
and 90 seconds.  Values were calculated using a standard curve of reduced 
glutathione.   
 Glutathione disulfide (GSSG) levels were determined following 2-
vinylpyridine derivatization (Griffith, 1980).  For GSSG levels, 25 µL of 
supernatant was combined with 175 µL water.  To this, 2 µL of triethylamine and 
4 µL of 2-vinylpyridine were added and the mixture was incubated for 30 min at 
room temperature.  Following the incubation, 700 µL of 0.3 mM NADPH was 
added with an additional 10-minute incubation at 30°C.  After this incubation, 100 
µL of 6 mM DTNB and 100 µL of glutathione reductase (16 units/mL) were 
added.  The samples were placed immediately into the spectrophotometer set at 
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 412 nm and the absorbance was read at 0, 15, 30, 60, and 90 seconds.  Values 
were calculated using a standard curve of GSSG.  
 
4-Hydroxynonenal-Adducted Protein  
Renal cortical slices (50-100 mg) were incubated with PAP (0, 0.1, or 0.25 
mM) for 90 min, as described. Tissues were weighed and homogenized in Krebs-
Ringer Buffer on ice in a 2 mL total volume.  Samples were stored a –80 °C until 
analysis.  Samples were thawed on ice.  Protein concentrations were determined 
for each sample (Bradford, 1976).  For each sample 150 mg protein equivalents 
were added, while H2O was added to provide equal volumes.  An equal volume 
of sample buffer was added and samples were boiled for 5 min.  Samples and 
standards were loaded onto a polyacrylamide gel (12.5 % acrylamide) and 
electrophoresed at 65 volts for 17 hr.  The gel was then transferred to a 
nitrocellulose membrane at 90 volts for 90 min.  To verify efficiency of transfer, 
the membrane was placed in Ponceau S stain for visualization.  The membrane 
was then rinsed with H2O at room temperature under constant shaking to remove 
stain.  The membrane was then blocked with milk at room temperature under 
constant shaking for 1 hr.  Rabbit polyclonal antibody to (E)-4-Hydroxynonenal 
(anti-HNE PAb) (Alexis Biochemicals, ALX-210-767) in blocking buffer was 
added and incubated overnight at 40 °C under constant shaking.  The membrane 
was then rinsed three times in TBST.  Secondary antibody, goat anti rabbit linked 
with horseradish peroxidase, in blocking buffer was added and incubated at room 
temperature under constant shaking for 90 min.  The membrane was then rinsed 
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 three times in TBST and once in TBS.  Enhanced chemiluminescence substrate 
was added and the membrane was wrapped in Saran wrap.  The membrane 
image was then transferred to Kodak Photographic film for visualization of 
4hydroxynonelal-adducted proteins.    
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